

Journal of Visualized Experiments

Method for High Speed Stretch Injury of Human Induced Pluripotent Stem Cell-Derived Neurons in a 96 Well Format

--Manuscript Draft--

| | |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| Article Type: | Methods Article - JoVE Produced Video |
| Manuscript Number: | JoVE57305R2 |
| Full Title: | Method for High Speed Stretch Injury of Human Induced Pluripotent Stem Cell-Derived Neurons in a 96 Well Format |
| Keywords: | Stretch; Neurotrauma; Neuron; human induced pluripotent stem cell; Silicone; cell culture; High Content Imaging |
| Corresponding Author: | John Finan NorthShore University Health System Evanston, IL UNITED STATES |
| Corresponding Author's Institution: | NorthShore University Health System |
| Corresponding Author E-Mail: | JFinan@northshore.org |
| First Author: | Jack Kuzmiak Phillips, BA |
| Other Authors: | Jack Kuzmiak Phillips, BA Sydney Ann Sherman Sevan R Oungoulian |
| Author Comments: | |
| Additional Information: | |
| Question | Response |
| If this article needs to be "in-press" by a certain date, please indicate the date below and explain in your cover letter. | |

TITLE:

Method for High Speed Stretch Injury of Human Induced Pluripotent Stem Cell-derived Neurons in a 96-Well Format

AUTHORS & AFFILIATIONS:

Jack K. Phillips¹, Sydney A. Sherman^{1,2}, Sevan R. Oungouljian³, John D. Finan¹

¹Department of Neurosurgery, NorthShore University HealthSystem, Evanston, IL, USA

²Midwestern University/Chicago College of Osteopathic Medicine, Downers Grove, IL, USA

³Independent Contractor, New York, NY, USA

CORRESPONDING AUTHOR:

John D. Finan (jfinan@northshore.org)

Telephone: +1 224 364 7578

EMAIL ADDRESSES of CO-AUTHORS:

Jack K. Phillips (jphillips2@northshore.org)

Sydney A. Sherman (ssherman88@midwestern.edu)

Sevan R. Oungouljian (sougouljian@gmail.com)

KEYWORDS:

Stretch, neurotrauma, neuron, human induced pluripotent stem cell, silicone, cell culture, high content imaging

SUMMARY:

Here we present a method for a human *in vitro* model of stretch injury in a 96-well format on a timescale relevant to impact trauma. This includes methods for fabricating stretchable plates, quantifying the mechanical insult, culturing and injuring cells, imaging, and high content analysis to quantify injury.

ABSTRACT:

Traumatic brain injury (TBI) is a major clinical challenge with high morbidity and mortality. Despite decades of pre-clinical research, no proven therapies for TBI have been developed. This paper presents a novel method for pre-clinical neurotrauma research intended to complement existing pre-clinical models. It introduces human pathophysiology through the use of human induced pluripotent stem cell-derived neurons (hiPSCNs). It achieves loading pulse duration similar to the loading durations of clinical closed head impact injury. It employs a 96-well format that facilitates high throughput experiments and makes efficient use of expensive cells and culture reagents. Silicone membranes are first treated to remove neurotoxic uncured polymer and then bonded to commercial 96-well plate bodies to create stretchable 96-well plates. A custom-built device is used to indent some or all of the well bottoms from beneath, inducing equibiaxial mechanical strain that mechanically injures cells in culture in the wells. The relationship between indentation depth and mechanical strain is determined empirically using high speed videography of well bottoms during indentation. Cells, including hiPSCNs, can be

cultured on these silicone membranes using modified versions of conventional cell culture protocols. Fluorescent microscopic images of cell cultures are acquired and analyzed after injury in a semi-automated fashion to quantify the level of injury in each well. The model presented is optimized for hiPSCNs but could in theory be applied to other cell types.

INTRODUCTION:

TBI is a major cause of mortality and morbidity in the United States, causing around 52,000 deaths and 275,000 hospitalizations every year¹. More than 30 clinical trials of candidate therapeutics for TBI have been conducted without a single success². This uniform failure suggests that human-specific processes separate human TBI from the pathophysiology observed in commonly used pre-clinical rodent models.

The advent of hiPSCNs has created an opportunity to study neurotrauma in a human *in vitro* model. Drug screening with hiPSCN-based models may deliver results that are more predictive of clinical success than models employing rodent cells. Also, hiPSCNs can be genetically manipulated to isolate and study the effect of individual human genetic variants on pathology³.

The method described in this manuscript is designed to bring the unique advantages of hiPSCN-based disease modeling to neurotrauma. *In vitro* stretch injury models of neurotrauma are well established⁴⁻⁶ with primary rodent cells and human neural cancer cell lines. Most of these models generate stretch by pneumatically loading a silicone membrane. This approach is effective in a single well format but has proven difficult to scale up to a multi-well format⁷. As a result, there has never been a high throughput screen for agents to treat stretch injured neurons.

In this model, the membrane stretches due to indentation from underneath with a rigid indenter. This approach has been shown repeatedly to generate clinically relevant pathology *in vitro* in single well systems⁸⁻¹⁰. Our recent work has shown that it easily scales up to a 96-well format while maintaining pulse durations on the order of tens of milliseconds¹¹, which is the time domain of closed head impact events^{12,13}.

In summary, the key advantages of this *in vitro* injury model are the 96-well format, the use of hiPSCNs, and the clinically relevant time domain of the insult.

PROTOCOL:

1. Silicone Detoxification

1.1. Cut 254 μ m thick, 30.48 cm x 30.48 cm silicone membranes into 7.5 cm x 11 cm rectangles using a razor blade and an acrylic template. 10 rectangular membranes can be made with each sheet. Save the paper that comes with the silicone.

1.2. Place the membranes in a tub of deionized (DI) water with glassware soap. One at a time, scrub the membranes vigorously with gloved fingertips for at least 20 s or until lathered.

1.3. Rinse the membranes under running DI water until the lathered soap is visibly removed. Lay the membranes on the paper (from their packaging) and autoclave on a gravity cycle.

1.4. Soak each silicone membrane in 250 mL of 70% ethanol per membrane on an orbital shaker at 60 rpm for 24 h. Use a container made from a material that does not react with ethanol, such as polypropylene.

1.4.1. If more than one membrane is placed in a single bin, or if the membranes stick to the bottom of the bin, separate the membranes from their environment with plastic pipette tips and pipette tip racks.

1.5. Transfer the silicone membranes with gloved hands to 250 mL of DI water per membrane and soak on the orbital shaker for 48 h at 60 rpm.

1.6. Lay the membranes back on the paper and place in a 93 °C glassware oven for 4 h.

1.7. Store the membranes on the paper, in a clean and dry place, covered with another sheet of paper to protect them from dust.

2. Plate Fabrication

2.1. Plasma treat a 96-well plate top with a 200 W plasma cleaner (see **Table of Materials**) for 60 s on high power, placing it bottom-side-up inside the plasma cleaner. Check for a purple glow visible through the window of the chamber, which indicates that an effective plasma has formed. This bonding technique is adapted from Sunkara *et al.*¹⁴

2.2. Within 60 s, place the plate top in 200 mL of 1.5% (3-Aminopropyl) triethoxysilane (APTES) in DI water for 20 min, bottom-side-down. This solution is unstable: prepare it no more than 60 s before introducing the plate.

Caution: Work with APTES in a fume hood.

2.3. Plasma treat an extracted silicone membrane in the plasma cleaner for 60 s on high power. Time the plasma treatment such that it finishes no more than 5 min before the end of the 20 min period in step 2.2.

2.4. Use forceps to position the plasma treated membrane on top of a 7.5 × 11 cm² parchment paper rectangle. Align a 7.5 cm x 11 cm x 0.5 cm aluminum slab on the lower portion of the plate fabrication clamp. Align the silicone membrane and parchment paper on the aluminum slab using forceps.

Note: Computer-aided design (CAD) files for this device are provided in the supplemental materials as a supplementary code file '**Press Die - Generic 3D.STEP**'. The associated bill of

materials is supplied in **Supplementary Table 1: Custom Built Devices – BOM.xlsx**.

2.5. Remove the plate tops from the APTES bath and shake off excess solution. Dip into a 200 mL DI water bath for 5 s and shake off excess water. Dip into a different 200 mL DI water bath for 5 s and shake off excess water. Replace the water in these baths before dipping another plate top.

2.6. Use compressed air to completely dry the plate top.

2.7. Place the plate top in the upper portion of the plate fabrication clamp. Gently close the plate fabrication clamp to press the plate top and silicone together. Clamp for at least 1 h.

2.8. Allow the plate to cure for 24 h at room temperature before use, protected from dust.

3. Stretching a Plate

3.1. Clean the indenters.

Note: See **Supplementary Figure 1**.

3.1.1. Prepare a 60 W bath-style sonicator with DI water at room temperature.

3.1.2. Support the indenter block above the sonicator bath, inverted so that only the tops of the indenters are submerged to a depth of at least 1 mm. Sonicate the indenters for 8 min at 42 kHz.

3.1.3. Blow dry the indenters with compressed air.

3.2. Align the indenter block.

3.2.1. Position a camera with a live feed above the stretching device so that it is looking down on the indenter array. Focus on the tops of the indenters.

Note: The setup described in Section 4, “Characterizing Membrane Stretch,” is one possible camera setup for this task.

3.2.2. Secure a plate on the stage of the injury device using the stage clamps (**Figure 1**) and place a dome light over the device.

Note: See the **Table of Materials** for the instrument control software.

3.2.3. Launch the instrument control software by clicking on the software icon on the desktop of the computer that is controlling the injury device. Run the “in_vitro_neurotrauma.lvproj” project by clicking on it in the launch window. From the project window, launch the motion control and position tracker virtual instruments (VIs), which are named ‘motion_control.vi’ and ‘position_tracker.vi’, respectively, by double-clicking on them.

3.2.4. Close the cage surrounding the injury device. Press the **arrow** button in the top left corner of the motion control VI to run the VI and click **Near Bottom** to lower the stage to within 2 mm of contacting the indenters. Click the **Stop** button to stop the VI.

Caution: Keep hands clear of the stretcher when manipulating the camera in the cage. The cage should be fitted with a door switch that delivers power to the stretching device only when the cage door is closed.

3.2.5. In the project window, right click on **Axis 1**. Click on **Interactive Test Panel**. In the window that opens, set the step size to 50 μm by entering '500' units in the **Target Position** field.

3.2.6. Click the green **go** button at the bottom of the **Interactive Test Panel** window repeatedly until the plate first makes contact with any indenters. Check for contact on the live image displayed by the camera. Note the vertical stage position reported in the top left of the **Interactive Test Panel** window; this is the first contact position.

3.2.7. Lower further (as described in step 3.2.6) until every well has made contact with the indenters. If necessary, move the camera to see the whole plate and move the stage up (by specifying a negative **Target Position**) and down. Note the vertical stage position reported in the top left of the window when all posts are in contact (this is the full contact position).

3.2.8. Note the difference between the first contact and full contact positions. Close the **Interactive Test Panel**. Run the **motion control VI** (see step 3.2.4) and click on **Top** to raise the stage. Stop the motion control VI with the **Stop** button.

3.2.9. Once the stage is at the top of its travel, open the door to deactivate the device. Adjust the set screws on the corners of the indenter block. Loosen the set screw on the corner that made contact first, to lower it and tighten the opposite screw to raise the corner that made contact last.

3.2.10. Repeat the process of lowering the stage until the plate contacts the indenters, inspecting the contact images for tilt, raising the stage, and adjusting (step 3.2.9) the indenter block. When the stage and block are aligned, all indenters will make contact at once.

3.2.11. Open the door to deactivate the device. Insert the tie-down screws into their holes on the indenter block and tighten them. Confirm that the block is level with the tie-down screws in place (steps 3.2.4–3.2.8). Take note of the stage position reported by the **Interactive Test Panel** when the plate makes contact. This will be the zero position for indentation experiments.

3.3. Lubricate the indenters.

3.3.1. If the indenter block has just been set up and has not yet been lubricated, clean a solid rubber pad (7.5 cm x 11 cm x 1.5 mm) and a soft, closed-cell foam rubber pad (7.5 cm x 11 cm x 3 mm) with an ethanol-soaked lab wipe. Allow them to air dry.

3.3.2. Soak a lab wipe in corn oil and spread it on the solid rubber pad to a dull shine.

3.3.3. Place the foam pad onto the solid rubber pad to transfer oil to the foam pad. Place a 7.5 cm x 11 cm x 0.5 cm aluminum slab on top of the foam pad and load it with a ballast weight of approximately 360 g (*e.g.*, 6 conical tubes loaded with 45 mL of water each) to ensure consistent transfer of oil from the solid rubber pad to the foam pad. Allow 10 s for the oil to transfer to the foam rubber pad.

3.3.4. Move the foam rubber pad onto the indenter array. Place the aluminum slab and the ballast weight on top of it to ensure consistent transfer of the oil to the tips of the indenters. Allow 10 s for the oil to transfer to the indenters.

3.3.5. If no plate has been stretched since the indenter block was set up and lubricated for the first time, stretch a test plate before beginning the experiment.

Note: This will prevent any inconsistency between the first stretch and subsequent stretches from confounding the experiment. For subsequent stretches, repeat only steps 3.3.2–3.3.5 before each stretch.

3.4. Stretch a plate.

3.4.1. Lubricate the indenters as described in step 3.3.

3.4.2. Secure the plate on the stage of the injury device with the stage clamps. If sterility is required, adjust the position of the lid to secure the plate without exposing the culture surface to room air.

3.4.3. Lower the stage to the zero-position using the **motion control VI** (see steps 3.2.4–3.2.6); zero-position is determined during step 3.2.

3.4.4. Change the file name in the “file path” field in the **position tracking VI** to a unique file name, then run it with the **arrow** button in the top left corner of that window.

3.4.5. Set the depth and duration of indentation (typically 1–4 mm and 30 ms, respectively, maximum depth 5 mm, minimum duration 15 ms) in the **Injury (mm)** and **Injury Duration (ms)** fields in the **movement control panel VI** by clicking on the fields and typing in the desired values.

3.4.6. Run the **movement control panel VI** and click on **Injure** to indent the plate.

3.4.7. Move the stage up to the top of its travel by clicking on **Top**. Then stop the VI with the **Stop** button and deactivate the injury device by opening the door.

3.4.8. Inspect the displacement history of the stage presented in the **position tracker VI** to confirm that the specified maximum displacement was applied. Right click on the graph and click on **export to Excel**. Click on **File | Save as** to save the data.

4. Characterizing Membrane Stretch

4.1. Paint the recess at the top of each indenter white to provide a high contrast background for high speed videography.

Caution: Do not paint the rims of the indenters where they make contact with plates.

4.2. 3D print with poly(lactic acid) (PLA), or otherwise fabricate, a cylindrical stamp with which to make a dot in each well. Make the cylinder 5.9 mm in diameter and 12.2 mm high, with a cylindrical protrusion 1.5 mm diameter and 1.0 mm high centered on top.

Note: A 3D printable model '**stamp.STL**' is available as a supplementary file.

4.3. Plasma treat the plate right-side-up to activate the silicone cell culture surface in the wells for 60 s, as mentioned in step 2.1.

4.4. Place the plate on a rubber pad or other soft surface. Prime the small protrusion on the stamp (see step 4.2) with ink from a permanent marker pen. Insert the stamp into the well to be tested and tap to ensure good transfer of ink. Prime the stamp before every well.

4.5. Align the indenter block and lubricate the indenters of the injury device (see steps 3.2–3.3). Clamp the plate onto the stage of the injury device. Position a bright diffuse axial light above the injury device.

4.6. Set up a high-speed camera on a boom stand over the injury device, facing straight downward, with the lens set to the smallest numbered f-stop, and turn it on. Launch the camera software on the computer connected to the camera. In the **frame rate** drop down menu, select **2,000** frames per second, and in the **shutter** drop down menu, select the fastest exposure time which yields high contrast images. Center over the dotted wells.

4.6.1. Position the camera so that the field of view contains 12 wells in a 3 x 4 grid.

Note: This field of view offers an optimal compromise between throughput and resolution for a 1,280 × 1,024 image.

4.7. Lower the plate to the zero-point (see steps 3.2.4–3.2.6). One-click the record button on the camera software so that it reads **trigger in**. Initiate the position tracker VI (step 3.4.4).

4.8. Turn on the bright diffuse axial light. Indent the plate as described in step 3.4.6.

4.9. Turn off the bright diffuse axial light.

4.10. On the camera control computer, find the 30–40 ms window of the recording in which the indentation occurs: drag the beginning and end arrows in the high-speed video play bar in the camera software. Click **Save**, set the name in the **File Name** field, select **TIFF** in the **Format** field, and click on **Save**.

4.10.1. Look through the .TIF-files for images of the least stretched (beginning) and most stretched (peak indentation) states.

4.10.2. To measure the height and width of the dots in both images, use Fiji to open the images of the least and peak stretch side-by-side. Using the default rectangular selection tool, click and drag to draw a box around a dot in the least stretch image. Measure the height and width with **Analyze | Measure**.

4.10.3. Repeat for the dot in the same well on the peak stretch image. Repeat for the rest of the wells.

4.11. Calculate the Lagrangian strain in the x and y directions as follows:

$$E_{xx} = \frac{X_f - X_i}{X_i} + \frac{1}{2} \left(\frac{X_f - X_i}{X_i} \right)^2$$

$$E_{yy} = \frac{Y_f - Y_i}{Y_i} + \frac{1}{2} \left(\frac{Y_f - Y_i}{Y_i} \right)^2$$

Note: Here, E_{xx} is the Lagrangian strain in the x direction, E_{yy} is the Lagrangian strain in the y direction, X is the width of the dot, Y is the height of the dot, $_f$ denotes the final image (*i.e.*, the peak indentation image), and $_i$ denotes the initial image (*i.e.*, the pre-indentation image). Average the two values to determine the strain in that well.

5. Plating the Cultured Cells

5.1. Autoclave the bins and ballast weights that will be used for sterilization.

5.2. Plasma treat the silicone-bottomed plates right-side-up for 60 s (see step 2.1). Immediately submerge the plates in sterile bins containing 70% ethanol for 15 min.

5.3. Submerge the plates in sterile phosphate buffered saline (PBS) in separate sterile bins for 30 min.

5.4. Aspirate the PBS from the wells. Only dry one plate at a time to prevent the wells from losing the plasma treatment.

Caution: Silicone bottomed plates provide less tactile feedback than rigid plates when pipetting and are more likely to block the tip of a pipette.

5.5. Add 100 μ L of 0.1 mg/mL poly-L-ornithine (PLO) per well to the sterilized plates. Incubate at room temperature for 1 h.

5.6. Rinse the wells twice with 100 μ L sterile PBS, leaving the second wash on the wells until the cell suspension is ready.

5.7. Remove the vial of hiPSCNs from liquid nitrogen storage using safety gloves and place on dry ice. Quickly transport the vial to a 37 °C water bath and thaw for exactly 3 min. Do not swirl the vial.

5.8. In a sterile hood, gently transfer the contents of the vial to a 50-mL conical tube using a 1 mL serological pipette.

5.9. Rinse the empty cryogenic vial with 1 mL of room temperature complete maintenance medium (media base + supplement).

5.10. Transfer the 1 mL of media into the 50-mL tube drop-wise at about one drop per second. Gently swirl the tube while adding. Add 8 mL of room temperature complete maintenance medium to the 50-mL tube at about 2 drops/s.

5.11. Cap the tube and invert 2–3 times. Count the cells with a hemocytometer. Compute the volume of the additional media required to dilute the cell suspension to 225,000 cells/mL.

5.12. Gently pipette the amount of media (calculated above) into the tube of cell suspension using a 25 mL serological pipette.

5.13. Add 10 μ L of 1 mg/mL laminin stock per 1 mL of cell suspension with a 1,000 μ L micropipette to achieve 10 μ g/mL of laminin in the cell suspension. Aspirate up and down once with the tip used for laminin, then cap the tube and invert the tube once.

5.14. Aspirate the PBS from the plates, one plate at a time. Use a multichannel pipette to add 100 μ L of the hiPSCN cell suspension to each well. The wells have a culture area of 0.33 cm², so the cell density per area is 67,500 cells/cm².

5.15. Rest the plates at room temperature for 15 min after seeding to promote attachment. To avoid fan vibrations of sterile culture hood, place the covered plates on the lab bench. Incubate the cultures at 37 °C with 5% CO₂.

5.16. Perform a full media change at 24 h, refilling the wells with 200 μ L of complete maintenance media. Perform a half media change of 100 μ L/well every 2–3 days.

6. Injuring Cultures

6.1. Align the indenter block and find the zero position as described in step 3.2. Lubricate the indenters as described in step 3.3.

6.2. Set the filename for the displacement history in the **position tracker VI** (step 3.4.4). Set the injury parameters in the **motion control VI** (step 3.4.5).

6.3. Take the plate to be injured out of the incubator and clamp it onto the stage. Adjust the position of the lid to secure the plate without exposing the cultures to room air.

6.4. Lower the plate to the zero-point (steps 3.2.4–3.2.6) using the **motion control VI**. Start the **position tracker VI** (step 3.4.4).

6.5. Use the movement control VI to indent the plate (as described in step 3.4.6). For sham stretches, skip only this step.

6.6. Return the stage to the top of its range of motion (see step 3.4.7). Return the plate to the incubator.

6.7. Inspect and save the displacement trace (as in step 3.4.8).

7. Microscopy

7.1. Prepare a 10x staining solution with 2 μ g/mL Hoechst 33342 and 5 μ g/mL Calcein AM in maintenance media.

7.2. Stain each well with a 20 μ L spike of 10x staining solution.

7.3. Incubate for 15 min with stain at 37 °C.

7.4. Acquire wide field fluorescent images. Use conventional FITC and DAPI filter sets to image the Calcein AM and Hoechst 33342 signals, respectively. If the multi-well imaging sequence will take more than 10 min, enclose the plate in a stage top incubator to maintain the health of the cultures.

Note: A 10x, 0.30 NA lens provides sufficient detail for determination of cell viability and morphology. Adjust gains to ensure good visualization of the neurites, even if this causes some saturation of the much brighter soma.

7.5. Segment live cell images in the green Calcein AM channel to identify soma and neurites. Use nuclear images in the blue Hoechst 33342 channel to assist with the identification of the soma.

REPRESENTATIVE RESULTS:

The stretcher device is capable of moving the stage repeatably with pulse durations as short as 10–15 ms depending on the amplitude of the pulse (**Figure 2A**). The pulse amplitudes are highly repeatable, but the pulse duration varies by approximately 1 ms between repetitions. The actual pulse amplitude diverges from the prescribed pulse amplitude when a large number of wells are loaded, and the prescribed amplitude is high (see **Figure 2B**). As the amplitude of stage displacement is increased beyond 3 mm, the actual displacement amplitude increasingly falls short of the prescribed displacement amplitude (see **Figure 2B**). Careful alignment of the post block eliminates any trend in the membrane strain across rows or columns (**Figure 2C**). At the 3.5 mm prescribed stage displacement amplitude (3.3 mm actual displacement amplitude) with 52 wells indented, the mean Lagrangian strain across all well locations was 0.451 (standard deviation of means for all locations = 0.051, mean of standard deviations for all locations = 0.065, $n = 5$ measurements per well). These results are presented here for completeness although some of them have already been reported¹¹.

An optimal, uninjured culture will have few if any clumps of more than 5 cells. Neurites will be individual, long, slender, and curved with little or no sign of tension or beading (**Figure 3A**). Under ideal conditions, the viability of the cultures should closely approach the viability specified in the manufacturer's data sheet (typically 60–70%) and cultures on silicone should resemble those maintained on conventional rigid culture substrates (**Figure 3B**). Neurites may or may not be visible on a low power bright field microscope. Laminin concentration and cell density both influence cultures at baseline and after injury. Increasing the cell density increased the number and size of clumps that formed in culture. Increasing the laminin concentration often counteracted this effect (**Figure 3A**). However, increasing the laminin concentration too much blunted the sensitivity of the cultures to injury (**Figure 4**). The optimal laminin concentration for uninjured cultures was 50 $\mu\text{g}/\text{mL}$ of laminin (**Figure 3**), but the optimal separation between the sham and stretch injured populations was obtained at 10 $\mu\text{g}/\text{mL}$ of laminin (**Figure 4**). Higher laminin concentrations reduced the sensitivity of the cultures to injury at short time points (**Figure 4**), but also improved baseline cell viability at longer time points (*e.g.*, 7 days). In summary, it is worthwhile to optimize the laminin concentration for each experimental scenario.

Membrane strain, post-injury imaging time point, laminin concentration, and cell density all exerted a highly statistically significant main effect on the neurite length per cell (ANOVA, $p < 0.001$). The effect of membrane strain on neurite length per cell had highly statistically significant interactions with post-injury imaging time point and laminin concentration (ANOVA, $p < 0.001$) and a statistically significant interaction with cell density (ANOVA, $p < 0.05$). Similarly, membrane strain, post-injury imaging time point, cell density, and laminin concentration all exerted a highly statistically significant main effect on cell viability (ANOVA, $p < 0.001$). The effect of the membrane strain on cell viability had a highly statistically significant interaction with the post-injury imaging time point (ANOVA, $p < 0.001$) and a statistically significant interaction with the cell density (ANOVA, $p < 0.05$). These results prove that timing, cell density, and laminin

concentration exert an important influence on the relationship between the applied insult and experimental outcomes, so each should be optimized carefully.

Low cell viability and beaded neurites, along with stunted neurite growth, indicate toxic culture conditions that can arise from improperly prepared silicone. Skipping or shortening the water soak or the oven dry can leave absorbed ethanol or water in the membrane, respectively, which can diffuse into the media and stress the cells. Well-injured cultures will have reduced cell viability, shortened or missing neurites, beaded neurites, and neurites that look taut or tensioned. Injury may induce clumping in cell cultures that were well-dispersed pre-injury. Large clumps can confound the morphological analysis. For morphological analysis, the injury level should be tuned such that noticeable changes occur, but cells are still present with some neurites.

FIGURE AND TABLE LEGENDS:

Figure 1: A labeled schematic of the injury device. (A) Top view, (B) isometric view, (C) front view, (D) right side view. The scale bar applies to the orthographic views (A, B and D).

Figure 2: Kinematics of the mechanical insult. (A) The stage displacement histories over 5 pulses at a range of prescribed amplitudes (prescribed amplitudes are listed in the legend) when no wells are loaded. (B) The stage displacement histories over 10 pulses at a range of prescribed amplitudes (prescribed amplitudes are listed in the legend) when 52 wells are loaded. (C) The average strain in each well with stage displacement amplitude of 3.3 mm ($n = 5$ measurements per well, average standard error per well = 0.029). Note that C4–F4 and C9–F9 are unstretched control wells. This figure has been modified from Sherman *et al.*¹¹

Figure 3: Optimization of culture conditions on silicone. (A) The effect of varying cell density and laminin concentration on hiPSCN cultures on silicone. Clumping increases with increasing cell density and decreasing laminin concentration. Cell density and laminin concentration must be optimized to achieve mono-dispersed cultures. Mono-dispersed cultures are less vulnerable to artifacts during quantification. Note that the dynamic range has been adjusted to optimize visualization of the neurites. As a consequence, the much brighter soma are saturated. This presentation is preferred to the alternative of optimizing the dynamic range with respect to the soma, which renders the much dimmer neurites almost invisible. The condition highlighted by the red square was deemed to be optimal for *in vitro* stretch injury experiments. (B) Under optimal conditions, cultures on silicone membranes appear similar to cultures on conventional rigid substrates. The left panel shows hiPSCNs cultured at 33,750 cells/cm² with 3.3 µg/mL of laminin on a conventional, rigid 96-well plate (the cell culture substrate is a tissue culture treated cyclic olefin co-polymer). The right panel reproduces the panel outlined in red from (A). Scale bars = 100 µm.

Figure 4: The injury phenotype and its dependence on laminin concentration. (A) Healthy culture, using 10 µg/mL laminin and 67,500 cells/cm². Neurites are long with no beads. There are few dead nuclei, and few clumps. (B) Culture using the same culture conditions, injured with 57% peak strain and imaged after 4 h. Neurites are shortened or missing, and some have beads

(indicated by arrows). There are fewer Calcein AM-positive cells and more Calcein AM-negative (*i.e.*, dead) nuclei. Injury has increased clumping among the surviving cells. (C) 4 h after injury, neurite length per cell declines with increasing strain in a manner that depends on the laminin concentration. (D) 4 h after injury, cell viability declines with increasing strain in a manner that depends on the laminin concentration. (E) 24 h after injury, neurite length per cell declines with increasing strain in a manner that depends on the laminin concentration. (F) 24 h after injury, cell viability declines with increasing strain in a manner that depends on the laminin concentration. (n = 4 per bar, error bars are ± 1 standard deviation, scale bars = 100 μm). Strain values are deduced from stage displacement using data from a prior publication by Sherman *et al.*¹¹

Supplementary Figure 1: Technical drawing of the indenter.

Supplementary Table 1: Custom Built Devices.

Supplementary Table 2: 96 Well Plate-loader Pinout Wiring Diagram.

Supplementary Code File 1: Computer-aided design drawings of the injury device.

Supplementary Code File 2: Computer-aided design drawings of the plate fabrication clamp.

Supplementary Code File 3: 3D representation of the stamp geometry, suitable for use with a 3D printer.

Supplementary Code File 4: SubVI for MuStLiMo_si_initialize.vi, which is a SubVI for motion_control.vi. Converts entries in dialog boxes into parameters for motion.

Supplementary Code File 5: SubVI for Multiple Straight Line Moves_simplified.vi, which is a SubVI for motion_control.vi. Converts entries in dialog boxes into parameters for motion.

Supplementary Code File 6: SubVI for position_tracker.vi. Counter tracks displacement input from linear encoder.

Supplementary Code File 7: Base LabVIEW Project.

Supplementary Code File 8: Top level VI that moves the device.

Supplementary Code File 9: SubVI for motion_control.vi. Executes the rapid displacement that stretches the plate.

Supplementary Code File 10: SubVI for motion_control.vi. Executes the slow displacement that moves the stage.

Supplementary Code File 11: SubVI for motion_control.vi. Plots a (usually undersampled) displacement history in the motion_control.vi control panel.

Supplementary Code File 12: Top level VI that records the displacement history.

Supplementary Code File 13: Contains Variable2, which communicates between motion_control.vi and position_tracker.vi.

Supplementary Code File 14: Schematic for printed circuit board.

Supplementary Code File 15: Layout for printed circuit board.

DISCUSSION:

The key to obtaining a consistent, biofidelic phenotype in this model is applying a consistent biofidelic mechanical insult. This model can generate pulse durations as short as 10–15 ms, which are similar to the pulse durations for human head impacts according to cadaveric experiments^{12,13}. The consistency of this insult depends on the alignment of the plate with the indenter block and consistent lubrication of the indenters. When the indenter block is well aligned, there is no trend in the applied strain across rows or columns (**Figure 2C**). A thin layer of lubricant typically creates less friction than a thick layer, and viscous greases are not recommended because they foul the silicone and obstruct the passage of light during microscopy. The actual stage displacement amplitude can fall substantially short of the prescribed displacement amplitude when many indenters are used, and the prescribed stage displacement amplitude is large (> 3 mm). However, while the actual displacement is less than the prescribed displacement at large amplitudes, it remains repeatable (**Figure 2B**). Therefore, large, actual displacements amplitudes can be reliably obtained by entering a prescribed value in excess of the desired value. Displacement amplitude matters only because it is an easily recorded proxy for the peak membrane strain, which directly measures the mechanical insult that induces pathology. Therefore, the procedure described for determining membrane strain from stage displacement is critical. This process should be repeated if any major changes are made to the system that affect the interaction between the plate and the indenters, for example if different diameter indenters, different indenter materials or coatings, or different types of silicone bottomed plate are used. The process of realigning the indenter block and determining the zero position should be repeated at the start of each experiment. A schematic of the stretching device is shown in **Figure 1**. CAD models required to reproduce the device are provided as supplemental materials: 'Injury Device - FULL ASSEMBLY - Generic 3D.STEP'; the associated bill of materials provided as 'Supplementary Table 1: Custom Built Devices - BOM.xlsx'. Also see **Supplementary Table 2 96 Well Plate _loader – Pinout Wiring Diagram.xlsx**, which describes the cabling connections that connect various components of the systems. **Interconnector_circuit_board.dip** describes a circuit board that interconnects the cables.

If the device is deactivated with the stage near the middle of its travel, the stage will move after the power is cut off because it is spring-loaded. When the power is restored, the feedback loop will detect a large difference between the last known prescribed position and the actual position. This will cause the stage to move suddenly to the position it was in when the device was deactivated. This sudden motion can cause errors in the output of the encoder, so care should

be taken to deactivate the device only when it is in its unpowered resting position at the top of its travel.

The fabrication clamp is designed to bring the plate body and silicone bottom together in a manner that allows optimal bonding. To this end, there are three key features in the design presented in the supplemental file '**Press Die - Generic 3D.STEP**'. First, the clamp plate body holder is parallel to the silicone bottom. If this is properly built, it will require no adjustment after the initial setup. Second, the layer of foam rubber in the clamp provides a small amount of compliance under the plate, as a completely rigid system would theoretically experience a sudden increase from zero clamping force to infinite clamping force when the clamp was closed. The position of the crossbar and set screw of the clamp are adjustable so that the distance between the two sides of the clamp can be fine-tuned.

Every effort should be made to provide a bright, white background behind the dot on the well bottom during strain characterization experiments. The better the contrast in these images, the easier it will be to automate the process of measuring the height and width of the dot, which can become tedious for a human operator analyzing a large experiment. High-speed videography of the bottom of a well in a 96-well plate presents challenges because the walls of the well tend to cast shadows. The use of a dome light or diffuse axial light that can illuminate along the line of sight of the camera without obscuring the image eliminates shadows or specular reflections that would arise with a conventional light source. The brightest available light source should be used because bright illumination allows images to be acquired with a short exposure time. Short exposure times minimize motion blur. Upgrading the light emitting diodes (LEDs) in the diffuse axial light allows shorter exposure times during high-speed video acquisition. The LEDs can be upgraded by opening the diffuse axial light, removing the stock LEDs, mounting 4 high power LED arrays to the back pane using LEDs holders, connecting them to a constant current power supply, and reassembling the diffuse axial light (see **Table of Materials** for catalog numbers). The disadvantage of upgrading the LEDs is that the passively cooled LEDs cannot be kept on for more than a few seconds due to the risk of overheating. Therefore, a different light is needed for alignment of the post-block and camera adjustment.

The presented method of quantifying membrane strain by measuring the dilation of a dot stamped on to the membrane is relatively crude, but it can scale up to multiple wells in a robust manner. The strain field across the well bottom can be characterized in more detail using digital image correlation. This technique involves spraying a speckled pattern onto the base of the well and then imaging it at high-speed during deformation. Commercial software can then be used to quantify strain at every point in the image by tracking the evolution of the speckled pattern.

This protocol produces a multi-faceted, clinically relevant, stretch injury phenotype in hiPSCNs. Cell death, neurite degeneration, and neurite beading are all well-documented sequelae of TBI in humans and animal models¹⁵. The key to success in this model is establishing and maintaining healthy cultures. Generally speaking, a cell culture protocol developed with conventional rigid plates is a worthwhile starting point for stretchable plate culture. However, the possibility that the cells in question may respond differently on silicone must always be considered. This is

particularly true of hiPSCNs, which are very sensitive to culture conditions. Some examples of optimizing cell density and laminin concentration are supplied in the **Representative Results** section (**Figure 3, Figure 4**). Activation of the silicone with plasma treatment is vital. Silicone is hydrophobic and unreactive; in its natural state, it will not bind to laminin or other molecules used to promote cell attachment. Plasma treatment renders the surface hydrophilic and exposes reactive groups. These changes allow adhesion molecules to bind to the silicone and promote cell attachment. It is important to note that the plasma treatment effect dissipates within minutes unless the surface is submerged in liquid, and so procedures that involve drying the activated surface should be performed as quickly as possible. A simple way to check if the effect of plasma treatment has worn off is to place a droplet of water on the surface. On untreated silicone, the droplet will bead up whereas on plasma treated silicone, it will spread out. With the hiPSCNs that we used (see **Table of Materials**), the manufacturer recommends adding the laminin with the cell suspension rather than pre-coating. This protocol has incorporated this approach successfully. While segmentation can, in theory, be accomplished with open source software or general-purpose programming languages, a high degree of proficiency with these tools is required to obtain good results. Neurites are frequently difficult to distinguish from background signal because they are so slender. Therefore, we recommend the use of commercial software tools distributed by high content microscopy companies with dedicated modules for segmentation and quantification of neurons, if they are available. Even with commercial software, it is wise to export images of the segmentation to visually verify accuracy.

There are some limitations associated with working in stretchable plates compared to working with conventional, rigid plates. Stretchable plates can be imaged as normal with air objectives. However, imaging with immersion objectives is very difficult. Lens oil may damage the silicone. Additionally, the objective exerts pressure on the silicone membrane as it moves upwards. This pressure displaces the membrane vertically, making it difficult to bring the sample into focus. The silicone membranes currently used in fabricating the plates are approximately 250 μm thick. This thickness exceeds the focal distance of many high power, immersion objectives. Special care must be taken to lay the membranes perfectly flat before clamping to achieve the flatness required for microscopy. Autofocus systems can compensate for deviations in the flatness of the finished plate to some extent. Future versions of the protocol may pre-tension the membrane before it is bonded to the plate top to ensure flatness. The adhesive-free procedure for bonding the silicone membrane to the plate top¹⁴ is considered an important strength of the current protocol. It eliminates the risk of neurotoxicity from the adhesive as well as any deviations in flatness due to non-uniform thickness of the adhesive layer.

Multi-electrode arrays are commonly used in experiments with hiPSCNs to assess their maturity and functionality. Unfortunately, these systems are incompatible with this model because the cell culture substrate is rigid. It is possible to create a stretchable multi-electrode array, although this has so far only been demonstrated in a single well format^{16,17}. Note that indenters can be removed individually from the indenter block so that some wells are not indented and can serve as shams. Removing the indenter prevents indentation but does not completely eliminate mechanical loading since there is still inertial motion of the fluid in the wells while the stage is moving. It is worth comparing *these* wells to wells in plates that were never subject to stage

698 motion to measure any pathological influence of fluid motion. Also, the array of indenters in the
699 block should be bisymmetric (symmetrical from front to back and side to side). This precaution
700 ensures that the plate is evenly loaded during indentation, so that the stage does not tilt sideways
701 and cause the rods to bind in their bearings.

702
703 One of the primary challenges to therapeutic innovation in neurotrauma is the complexity and
704 heterogeneity of the condition. Trauma applies multi-modal stress to every cell type in the central
705 nervous system simultaneously. Neurons have been reliably generated from human induced
706 pluripotent stem cells (hiPSCs) and are now widely available from commercial vendors.
707 Innovation is proceeding quickly in this field, and other neural cell types such as astrocytes¹⁸ and
708 microglia¹⁹ are also being derived from hiPSCs. It may soon be possible to isolate the cell-
709 autonomous responses of each of these cell types to trauma *in vitro* and then to co-culture
710 different cell types to understand how they communicate after trauma. In this way, it may
711 ultimately be possible to recreate the clinical challenge from the bottom up to thoroughly
712 understand it in a human system. This approach is distinct from the conventional approach
713 relying on rodent models and has the potential to generate novel insights that lead to the first
714 therapies for this common, devastating, and intractable condition.

715 716 **ACKNOWLEDGMENTS:**

717 This work is supported in part by a grant from the National Institutes of Health (R21NS098129).
718 We would like to acknowledge excellent technical assistance from SueSan Chen, Jonathan Tan,
719 Courtney Cavanaugh, Shi Kai Ng and Feng Yuan Bu, who designed and built a structure to support
720 lights used during high speed imaging experiments described in this manuscript.


721 722 **DISCLOSURES:**

723 The authors have nothing to disclose.


724 725 **REFERENCES:**

- 726 1 Faul M, X. L., Wald MM, Coronado V. *Traumatic brain injury in the United States:*
727 *emergency department visits, hospitalizations, and deaths, 2002–2006.*, (2010).
- 728 2 Kabadi, S. V. & Faden, A. I. Neuroprotective strategies for traumatic brain injury:
729 improving clinical translation. *Int J Mol Sci.* **15** (1), 1216-1236, doi:10.3390/ijms15011216, (2014).
- 730 3 Kiskinis, E. *et al.* Pathways disrupted in human ALS motor neurons identified through
731 genetic correction of mutant SOD1. *Cell Stem Cell.* **14** (6), 781-795,
732 doi:10.1016/j.stem.2014.03.004, (2014).
- 733 4 Smith, D. H., Wolf, J. A., Lusardi, T. A., Lee, V. M. & Meaney, D. F. High tolerance and
734 delayed elastic response of cultured axons to dynamic stretch injury. *J Neurosci.* **19** (11), 4263-
735 4269 (1999).
- 736 5 Wolf, J. A., Stys, P. K., Lusardi, T., Meaney, D. & Smith, D. H. Traumatic axonal injury
737 induces calcium influx modulated by tetrodotoxin-sensitive sodium channels. *J Neurosci.* **21** (6),
738 1923-1930 (2001).
- 739 6 Lusardi, T. A., Wolf, J. A., Putt, M. E., Smith, D. H. & Meaney, D. F. Effect of acute calcium
740 influx after mechanical stretch injury in vitro on the viability of hippocampal neurons. *J*
741 *Neurotrauma.* **21** (1), 61-72, doi:10.1089/089771504772695959, (2004).


- 742 7 Magou, G. C. *et al.* Engineering a high throughput axon injury system. *J Neurotrauma*. **28**
743 (11), 2203-2218, doi:10.1089/neu.2010.1596, (2011).
- 744 8 Morrison, B., 3rd, Cater, H. L., Benham, C. D. & Sundstrom, L. E. An in vitro model of
745 traumatic brain injury utilising two-dimensional stretch of organotypic hippocampal slice
746 cultures. *J Neurosci Methods*. **150** (2), 192-201, doi:10.1016/j.jneumeth.2005.06.014, (2006).
- 747 9 Cater, H. L. *et al.* Stretch-induced injury in organotypic hippocampal slice cultures
748 reproduces in vivo post-traumatic neurodegeneration: role of glutamate receptors and voltage-
749 dependent calcium channels. *J Neurochem*. **101** (2), 434-447, doi:10.1111/j.1471-
750 4159.2006.04379.x, (2007).
- 751 10 Kang, W. H. & Morrison, B., 3rd. Functional tolerance to mechanical deformation
752 developed from organotypic hippocampal slice cultures. *Biomech Model Mechanobiol*. **14** (3),
753 561-575, doi:10.1007/s10237-014-0622-4, (2015).
- 754 11 Sherman, S. A. *et al.* Stretch Injury of Human Induced Pluripotent Stem Cell Derived
755 Neurons in a 96 Well Format. *Sci Rep*. **6** 34097, doi:10.1038/srep34097, (2016).
- 756 12 Hardy, W. N. *et al.* Investigation of Head Injury Mechanisms Using Neutral Density
757 Technology and High-Speed Biplanar X-ray. *Stapp Car Crash J*. **45** 337-368 (2001).
- 758 13 Hardy, W. N. *et al.* A study of the response of the human cadaver head to impact. *Stapp*
759 *Car Crash J*. **51** 17-80 (2007).
- 760 14 Sunkara, V. *et al.* Simple room temperature bonding of thermoplastics and
761 poly(dimethylsiloxane). *Lab Chip*. **11** (5), 962-965, doi:10.1039/c0lc00272k, (2011).
- 762 15 Johnson, V. E., Stewart, W. & Smith, D. H. Axonal pathology in traumatic brain injury. *Exp*
763 *Neurol*. **246** 35-43, doi:10.1016/j.expneurol.2012.01.013, (2013).
- 764 16 Lacour, S. P. *et al.* Flexible and stretchable micro-electrodes for in vitro and in vivo neural
765 interfaces. *Med Biol Eng Comput*. **48** (10), 945-954, doi:10.1007/s11517-010-0644-8, (2010).
- 766 17 Yu, Z. & Morrison, B., 3rd. Experimental mild traumatic brain injury induces functional
767 alteration of the developing hippocampus. *J Neurophysiol*. **103** (1), 499-510,
768 doi:10.1152/jn.00775.2009, (2010).
- 769 18 Tcw, J. *et al.* An Efficient Platform for Astrocyte Differentiation from Human Induced
770 Pluripotent Stem Cells. *Stem Cell Reports*. **9** (2), 600-614, doi:10.1016/j.stemcr.2017.06.018,
771 (2017).
- 772 19 Muffat, J. *et al.* Efficient derivation of microglia-like cells from human pluripotent stem
773 cells. *Nat Med*. **22** (11), 1358-1367, doi:10.1038/nm.4189, (2016).
- 774




A











B



C







| Name of Material/ Equipment | Company |
|------------------------------------|---------------------------------|
| .010" Silicone Sheet | Specialty Manufacturing, Inc |
| Sparkleen | Fisher Scientific |
| Nunc 256665 | Fisher Scientific |
| Kim Wipes | ULINE |
| Plasma Cleaner | Harrick Plasma |
| (3-Aminopropyl) triethoxysilane | Sigma-Aldrich |
| Parchment Paper | Reynolds |
| Dome Light | CCS inc |
| Dome Light Power Supply | CCS inc |
| Axial Diffuse Lighting Unit | Siemens |
| High Power LED Array | CREE |
| LED holder | Molex |
| LED power supply | Mean Well |
| FastCam Viewer software | Photron |
| Fastcam Mini UX50 | Photron |
| Micro-NIKKOR 105mm f/2.8 | Nikon |
| 0.1 mg/mL Poly-L-Ornithine | Sigma-Aldrich |
| iCells | Cellular Dynamics International |
| iCell media | Cellular Dynamics International |
| iCell supplement | Cellular Dynamics International |
| Laminin | Sigma-Aldrich |
| Hoechst 33342 | Fisher Scientific |
| Calcein AM | Fisher Scientific |
| voice coil actuator | BEI Kimco |
| optical linear encoder | Renishaw |
| servo drive | Copley Controls |
| Controller | National Instruments |
| cRIO chassis | National Instruments |
| digital input module | National Instruments |
| data acquisition chassis | National Instruments |
| LabVIEW | National Instruments |
| hiPSCNs | Cellular Dynamics International |

| Catalog Number | Comments/Description |
|----------------------------------------|-----------------------------------|
| #70P001200010 | Polydimethylsiloxane (PDMS) sheet |
| #043204 | |
| #12-565-600 | Bottomless 96 Well Plate |
| S-8115 | |
| #PDC-001-HC | |
| #440140 | APTES |
| N/A | |
| LFX2-100SW | |
| PSB-1024VB | |
| Nerlite DOAL-75-LED | Diffuse axial light |
| XLamp CXA2540 | High Power LED Array |
| 1807200001 | LED Holder |
| HLG-320H-36B | Constant Current Power Supply |
| | camera software |
| N/A | High Speed Camera |
| #1455 | High Speed Camera Lens |
| #P4597 | |
| #NRC-100-010-001 | |
| #NRM-100-121-001 | |
| #NRM-100-031-001 | |
| #L2020 | |
| #H3570 | |
| #C3099 | |
| LA43-67-000A | |
| T1031-30A | |
| Xenus XTL | |
| cRIO 9024 Real Time PowerPC Controller | |
| cRIO 9113 | |
| NI 9411 | |
| NI 9113 | instrument control software |



1 Alewife Center #200
 Cambridge, MA 02140
 tel. 617.945.9051
 www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Method for High Speed Stretch Injury of Human Induced Pluripotent Stem Cell-Derived Neurons in a 96 Well Format

Author(s):

Jack K Phillips, Sydney A Sherman, John D Finan*

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/author>) via: ☐ Standard Access ☒ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in Section 3 above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This Section 5 applies if the "Standard Access" box has been checked in Item 1 above or if no box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to Section 7 below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in Item 2 above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:

John D Finan

Department:

Neurosurgery

Institution:

NorthShore University HealthSystem

Article Title:

Method for High Speed Stretch Injury of Human Induced Pluripotent Stem Cell-Derived Neurons in a 96 Well Format

Signature:



Date:

9/1/2017

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Editorial comments:

1. The manuscript has been modified. Please read it carefully and revise if necessary. Enclosed please find the top copy. Please do not change the current format/font.

2. Please rephrase the Summary to clearly describe the protocol and its applications in COMPLETE SENTENCES between 10-50 words: “Here, we present a protocol to ...”.

The summary has been revised for style.

3. Please remove citations (1 and 2) from the Abstract.

These citations have been removed.

4. JoVE policy states that the video narrative is objective and not biased towards a particular product featured in the video. The goal of this policy is to focus on the science rather than to present a technique as an advertisement for a specific item. If you are using a commercial software, for example, the term may be introduced but please use it infrequently and when directly relevant. Otherwise, please refer to the term using generic language. However, the details of using the software (commercial or non-commercial) should be provided for the reader to be able to reproduce your work.

The manuscript has been edited to add back in references to specific software and, by extension, instructions on how to use the specific commercial software we use.

5. For steps that involve software or analyzing tools, please make sure to provide all the details such as “click this”, “select that”, “observe this”, etc. Please mention all the steps that are necessary to execute the action item. Please provide details so a reader may replicate your analysis including buttons clicked, inputs, screenshots, etc. This is the level of detail we’re looking for. Please keep in mind that software steps without a graphical user interface cannot be filmed.

Specific, click-by-click instructions have been added throughout the manuscript.

6. Please ensure you answer the “how” question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action.

7. Please leave a blank line between all protocol steps as well as Notes.

8. Protocol: 1.3: “Rinse” with how much water? How to wash? Which pipette size used?

This is performed with running DI water from the DI water tap. This has been noted.

9. Protocol: 1.6: How to transfer? Using what?

Transfer with gloved hands. This has been noted.

10. Protocol: 2.1: Please provide an appropriate reference for plasma treat.

A reference has been added to the paper that inspired our approach to bonding silicone. Additional details have also been added regarding the plasma treatment.

11. Protocol: 2.7: Please provide enough guide for the reader to be able to build similar device.

CAD drawings and a dedicated bill of materials have been added to the supplemental files to allow the reader to build the device.

12. Protocol: 3.2.3: Please include all the buttons clicked in the software.

The button sequence has been added.

13. Protocol: 3.2.4, 3.2.5, etc.: If using any software, please include all the buttons clicked and all the setting selected.

The button sequence has been added.

14. Protocol: 3.26: Please clearly describe the actions. "Raise" how?

The button sequence has been added.

15. Protocol: 3.2.7: "Deactivate the device" how is that done?

The device is deactivated by opening the door. This has been noted.

16. Protocol: 3.2.8: How is the adjustment done?

As in the preceding step. This has been noted.

17. Protocol: 3.2.9: Insert what? Please clearly describe the actions.

Insert the tie down screws. The word order has been changed to disambiguate this.

18. Protocol: 3.4.1: How is that done? With what?

Lubricating the indenters is described in the preceding step, "lubricating the indenters." This has been noted.

19. Protocol: 3.4.3: Please describe how to use the software, please include all the buttons clicked.

The reader has been directed to 3.2.

20. Protocol: 3.4.4: How to run? Which button clicked?

The button sequence has been added.

21. Protocol: 3.4.5: How to do that? Please include all the buttons clicked and all the icons selected.

The button sequence has been added.

22. Protocol: 3.4.6: How is that done?

The button sequence has been added.

23. Protocol: 3.4.7: Caution: Please move this Caution to the Discussion.

The caution statement has been moved to the discussion.

24. Protocol: 3.4.8: How is the software used? How to save the displacement trace? Please include all the buttons clicked.

The button sequence has been added.

25. Protocol: 4.2: Please guide the reader to the supplementary materials, please mention the .stl file you provided.

Mention of the supplementary file has been added.

26. Protocol: 4.9: Please describe the actions of using the software, please include all the buttons clicked. We need all the details, this protocol will be used later by our script writers for the video production, the details of all actions are necessary.

The button sequence has been added.

27. Protocol: 4.13: How to save the file. Which button clicked?

The button sequence has been added.

28. Protocol: 4.15: Please describe using the software or refer to appropriate references.

A description of this using ImageJ has been added.

29. Protocol: 5.2: "as above"? Please include the step number.

2.1. The step number has been noted.

30. Protocol: 5.6: How is that done?

Step has been clarified: Add the PLO, let sit for one hour.

31. Protocol: 5.8: using what?

Safety gloves. This has been noted.

32. Protocol: 5.15: How? Using what?

By adding media. The exact amount will vary depending on the number of cells and desired volume. This has been noted.

33. Protocol: 5.16: How is that done? How to mix? Which pipette size used?

A 1000 μ L micropipette is used and this is now stated in the text. The step has been changed to clarify that 10 μ g/mL final concentration of laminin is achieved with 10 μ L of 1 mg/mL stock per mL of cell suspension. It has also been updated to instruct the reader to mix by inverting the tube.

34. Protocol: 6.3: Please describe how to use the software? Please include all the buttons clicked.

The reader has been referred to steps 3.4.3 and 3.4.4.

35. Protocol: 6.5, 6.6, 6.9: How is the software used?

The reader has been referred to steps 3.4.3, 3.4.4, 3.4.6, 3.4.7, and 3.4.8.

36. Protocol: 7.5: Note: Please move the discussion to the Discussion section. Please move this Note to the Discussion.

This note has been moved to the discussion. 37. After revising the protocol, please highlight 2.75 pages or less (currently that is more than 4 pages) of the Protocol (including headings and spacing) that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol. Remember that non-highlighted Protocol steps will remain in the manuscript, and therefore will still be available to the reader.

38. Please include all relevant details that are required to perform the step in the highlighting. For example: If step 2.5 is highlighted for filming and the details of how to perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be highlighted.

39. Please discuss all figures in the Representative Results. However, for figures showing the

experimental set-up, please reference them in the Protocol. Figure 1 is not mentioned in the representative results. It is discussed in the Discussion after other figures. Please revise accordingly.

Figure 1 is now referenced in the Protocol before the other figures referenced by the representative results.

40. Please provide a title and description for the SI file (.stl).

A title and description have been added during submission

41. If you are reusing figures from a previous publication, you must obtain explicit permission to re-use the figure from the previous publisher (this can be in the form of a letter from an editor or a link to the editorial policies that allows you to re-publish the figure). Please upload the text of the re-print permission (may be copied and pasted from an email/website) as a Word document to the Editorial Manager site in the "Supplemental files (as requested by JoVE)" section. Please also cite the figure appropriately in the figure legend, i.e. "This figure has been modified from [AUTHOR] et al.[REFERENCE]".

An email thread with the nature permissions desk, along with the full text of the Creative Commons Attribution 4.0 International license, was attached. In the figure 2 description, "Portions of this figure and this legend were reproduced from a prior publication by Sherman *et al.*¹³" has been changed to "This figure has been modified from Sherman *et al.*¹³"

42. Please revise the table of the essential supplies, reagents, and equipment. The table should include the name, company, and catalog number of all relevant materials in separate columns in an xls/xlsx file. Please list all the materials, equipment, instrument, and software used in your work.

Materials for building the injury device from the initial submission have been added back in.

We thank both the Editor and the Reviewers for their thoughtful and insightful comments. We feel that the process of addressing their concerns has considerably strengthened the manuscript.

Editorial comments:

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. The JoVE editor will not copy-edit your manuscript and any errors in the submitted revision may be present in the published version.

We have made minor changes throughout the document.

2. Please remove all commercial language: Sparkleen, catalog numbers, PowerPC, National instruments, LabVIEW VI, Kimwipe, etc.

We have removed commercial language. Section 8 of the original manuscript was specific to the commercial high content microscopy software that we used to analyze our images. To accommodate the prohibition of commercial language, we have rephrased this in more general terms and included a caution statement recommending the use of a commercial tool generated by professional software engineers for this step without specifying any of the several viable choices in the marketplace.

3. Manuscript, Figure 1 and 2: Please use SI units, e.g. use “ μL ” instead of “ μl ”. Please ensure that the L in these abbreviations are capitalized.

We have corrected liters to a capital L, and corrected imperial units.

4. Please ensure that all text in the protocol section is written in the imperative tense as if telling someone how to do the technique (e.g., “Do this,” “Ensure that,” etc.). The actions should be described in the imperative tense in complete sentences wherever possible. Any text that cannot be written in the imperative tense may be added as a “Note.” However, notes should be concise and used sparingly. Please include all safety procedures and use of hoods, etc.

We have made minor changes throughout the document, and rearranged some text to conform.

5. Please ensure you answer the “how” question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action.

We have made minor changes throughout the document.

6. The Protocol should be made up almost entirely of discrete steps without large paragraphs of text between sections. Please simplify the Protocol so that individual steps contain only 2-3 actions per step and a maximum of 4 sentences per step.

We have made changes throughout the document and moved some text to the discussion.

6. Some additional details are needed in the protocol:

1.6: Please use the Celsius grade.

Done

2.10: Cure plate where and at what temperature?

At room temperature. This has been stated specifically in the text.

3.2.3: What other parameters for sonication are used?

8 minutes in at 42,000 Hz in a 60W device in DI water. This has been stated specifically in the text.

3.3.2: Secure the plate how?

The plate is secured with clamps. Figure 1 has been added to illustrate the clamps on the device. References to securing the plate throughout the protocol have been updated to make clear that the plate is secured with clamps.

3.4.3: How many seconds exactly?

10. This has been added.

Remove what?

The foam pad and the components that weight it down. This step has been reworded for greater clarity.

4.2: Please provide an stl file.

An .stl file is being provided.

4.3: What are the plasma treatment parameters? Same as before?

Yes. This has been clarified in the text.

7. In the JoVE Protocol format, “Notes” should be concise and used sparingly. They should only be used to provide extraneous details, optional steps, or recommendations that are not critical to a step. Any text that provides details about how to perform a particular step should either be

included in the step itself or added as a sub-step. Please consider moving some of the notes about the protocol to the discussion section.

The text block at the start of 3.1.1 has been cut in light of this comment and a related comment from Reviewer #1 and moved to the end of the first paragraph of the Discussion.

8. Please highlight 2.75 pages or less of the Protocol (including headings and spacing) that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol. Remember that non-highlighted Protocol steps will remain in the manuscript, and therefore will still be available to the reader.

An appropriate subset of the protocol has been highlighted.

9. Please ensure that the highlighted steps form a cohesive narrative with a logical flow from one highlighted step to the next. Please highlight complete sentences (not parts of sentences). Please ensure that the highlighted part of the step includes at least one action that is written in imperative tense.

As above.

Reviewers' comments:

Reviewer #1:

Manuscript Summary:

The paper titled "Method for High Speed Stretch Injury of Human Induced Pluripotent Stem Cell-Derived Neurons in a 96 Well Format" aims to present a platform for studying brain injury in vitro with human-derived neuronal cultures. While stretch injury models have been used for many years to study mechanisms of trauma in neuronal cultures, this paper focuses on two specific challenges in this field which would make the technique attractive to researchers: (1) Increased throughput and (2) incorporation of Human cell lines. In general, the paper describes the necessary components required for this method to be reproduced successfully, and therefore I recommend it for publication, given that the subsequent issues are addressed.

Major Concerns:

1. There needs to be a general increase in the amount of quantification of mechanics associated with the model. Previous stretch devices were designed to generate highly reproducible strain and strain rates as these have been shown to be critical for neuronal injury. The major limitation of moving to high throughput is the risk of losing precision in the injury across samples. In its current form, I have no idea of how precise this instrument is and this would be my single hesitation in using it. There are many instances in which the authors describe potential pitfalls and subsequently offer suggestions as to how to avoid these, however, these are not sufficient. Expanding on this, the use of a voice coil actuator is a clever design, however, plate trajectories and induced substrate strain traces need to be included. I would want to see that the PID controller combined with the voice coil is sufficient to accurately produce specific strain and strain velocity profiles. Furthermore, to be complete I would also include traces with indenters

partially and fully loaded in order to vary the load on the coil.

Figure 2 has been added to quantify the kinematics of the device in detail. Panels B and C are reproduced from a prior publication¹ under the terms of the Creative Commons license governing that publication. Panel A is a new figure of freshly generated data that allows the reader to compare the motion of the device when the plate is loaded with 52 posts to the motion when not loaded. This addresses the concern raised in the last sentence of the above paragraph. Also, numerical results have been added to the first paragraph of the Representative Results quantifying the variability in the mechanical strain across wells and plates.

2. The figures included to support this technique are fairly weak. The multi-panel indicating the relationship between Laminin concentration and cell density is minimally helpful.

Cell density and laminin concentration are the two experimental parameters that most strongly influence the health of the cultures on silicone. These parameters cannot be optimized independently because one influences the other, as explained by the figures. Furthermore, optimizing uninjured cultures is not sufficient. Cell density and laminin concentration also influence the injury phenotype. This fact is also illustrated by the figures. These trends are vital to the design of successful experiments. We have included these figures to illustrate these trends to those who wish to use this technique in the hope that it will accelerate their efforts to optimize their cultures.

It is also over-saturated.

While calcein AM evenly labels the entire cytoplasm, the neurites are much fainter structures than the soma because their volume is much smaller. In these images, the dynamic range is intentionally adjusted to optimize visualization of the neurites. This adjustment inevitably leads to some saturation of the soma but this is worthwhile because the morphology of the neurites is more important in this context than the internal features of the soma. This practice is standard in the field²⁻⁴. The reviewer's concern is understandable because we neglected to explain this in our previous draft. We have explained this choice in the legend for Figure 3 of the revised manuscript. This point is also addressed in step 7.4 in the revised manuscript.

The inclusion of time points or comparison to controls would be informative.

We have added data from the 24 hour post-injury time point so that it can be compared to the 4 hour post-injury time point that was originally presented.

For example, you might include an example of an optimal culture at several time points next to a control dish using the manufacturer's protocol to illustrate minimal differences in culture quality metrics such as those provided in the following figure. Such a figure would provide an example for the appearance of a quality sample as well as provide evidence for the optimization of the culture protocol on the required flexible silicone substrate.

Figure 3B in the revised manuscript has been added to allow comparison of cultures on conventional rigid substrates with cultures on the required, flexible, silicone substrate.

The second figure is also fairly weak. Even if we are not reviewing for quality of data, my primary concern is that this figure doesn't emphasize the strength of the technique that is being described in the paper. I am assuming that this entire dataset is generated from 1 well, which should be emphasized if true in order to highlight the high throughput nature of the device.

This entire data set was not generated from a single well. It was also not generated from a single plate. All the wells in a plate must be injured with the same strain. Therefore, an experimental design that requires multiple strain levels must include multiple plates.

Proper statistics should also be included, again to highlight the sheer volume of data that can be generated from a single plate.

We have added ANOVAs identifying which main and interaction effects in each data set are statistically significant. The results of these statistical tests are presented in the third paragraph of the Representative Results in the revised manuscript.

The injury levels should also be presented in proper units. Why indicate a 1 mm vs 2 mm indentation, which tells me nothing, when the actual numbers of strain have been measured.

The categorization of data by displacement has been replaced with categorization of data by strain in Figure 4 of the revised manuscript.

Also, it is unclear how neurite length was calculated. Clarifying this with an image would be helpful.

It is difficult to be highly specific about how neurite length was calculated because we used commercial software for this purpose and the Editor has asked us to eliminate all commercial language from the revised manuscript. We have rewritten section 7 to address this concern while also respecting the Editor's wishes on this point.

Minor Concerns:

1. Implementation of this technique requires multiple custom fabricated parts. It is understood that these parts are difficult to describe in the text alone, but it will be essential to include drawings with necessary dimensions. For instance, section 3.1.1 describing the stretching plate is not sufficient to reproduce the device. From the text, it is also unclear if one will have to write the necessary supporting LabVIEW scripts or if they are provided.

The reviewer raises an important point about the challenges of describing a protocol that requires custom-built tools. The process of building the device is not a part of this protocol and the editor has specifically instructed us not to include material that is beyond the scope of the protocol. We have included a schematic of the device to better orient the reader as Figure 1 in the revised manuscript. We consider a complete set of technical documents necessary to reproduce the device (technical drawings with tolerances, bills of materials, LabVIEW code etc.) inappropriate for publication in the peer-reviewed literature so we will instead make them available to interested groups by informal communication. We have specified in the first paragraph in the Discussion of the revised manuscript that these documents are available upon request. When we

share these documents, we will do so on an “as is” basis to assist those interested in reproducing our device. However, if we included these numerous, detailed documents as part of this publication, we would commit ourselves to guaranteeing that every single document is without error and might in theory have to retract the paper or publish an erratum over an inconsistency in the drawings or a bug in the code. Guaranteeing this level of accuracy across all these numerous documents would substantially delay publication of the paper. Therefore, we feel that informal communication is the more appropriate method for disseminating this information.

2. Section 4 may be one of the most important for producing consistent injuries across laboratories, and the depth of the text is appreciated. However, I suggest including a table of measured values and expected variability.

Figure 2 in the revised manuscript provides results on measured strains and variability. These parameters are also quantified in the first paragraph of the Representative Results section in the revised manuscript.

Please also include a statement about the expected calibration requirements - how often, is the full procedure with high-speed camera necessary each time.

Our practice is to repeat the indenter-block alignment step (3.3) every time we wash the indenter (i.e. for every experiment) and to repeat characterization of membrane stretch (section 4) any time we alter the indenters or the plates. This practice is now described at the end of the first paragraph in the Discussion in the revised manuscript.

3. Given the importance presented within the paper on substrate preparation, it would be informative to provide control images of neurons cultured using the manufacturer’s protocol. It would be helpful to clarify in section 5 the differences in culture methodology for the iCell neurons on glass vs stretchable surfaces. In my experience, culturing neurons on stretchable surfaces is always more difficult compared to rigid surfaces, so this section may be best utilized to highlight these differences and simply direct the researcher to the iCell protocol for steps that adhere to the manufacturer’s protocol.

Figure 3B in the revised manuscript allows comparison of cells cultured on conventional rigid substrates according to the manufacturer’s protocol with cells cultured on silicone using our optimized protocol.

4. The discussion addresses the "...primary physical driver of variability in the system..." and there are suggestions for minimizing this error. However, there needs to be numbers included to inform the researcher how much variability to expect. The primary allure to this type of technique is the ability to injure many wells simultaneously. However, I don't have any idea what sort of variability to expect across wells within a single stretch as well as within a well across multiple stretches. These numbers will be useful both when assembling this type of device as well as for proper experimental design.

The newly added Figure 2 provides quantitative results describing measured strains and their variability. Numerical results quantifying the variability in strains across wells in a single plate and from plate to plate have been added to the first paragraph of the Representative Results section of the revised manuscript.

Reviewer #2:

Manuscript Summary:

This is a very nice piece of work, which will constitute an important contribution to the literature. The authors are commended for their efforts. A number of minor points need addressing before the paper can be fully accepted for publication.

Major Concerns:

None

Minor Concerns:

(1) Protocol 1.2. Was this washing only with H₂O?

Membranes are washed with soapy water. Section 1.2 has been reworded to be more explicit on this point.

(2) Plate Fabrication steps 2.2 and 2.3. What is the actual time (text says "at the last minute")? What is the time between rinses?

APTES solution should be diluted no more than 60 seconds before the introduction of the plate. The text has been updated to clarify this point.

(3) Section 3. A picture or schematic of the apparatus would be helpful.

A schematic of the apparatus has been added to the revised manuscript as Figure 1.

(4) Section 3.4.1. Was the water de-ionised?

Yes, but it does not need to be. The tubes of water simply function as ballast in this step. This passage has been reworded for greater clarity on this point.

(5) Section 3.5.5. What is the full range? The typical range is interesting too.

The typical range of plate displacements is 1-4mm. The maximum is 5mm. These values have been added to the text.

(6) Section 4.2. 3D printing us stated. Is this necessary or could it be fabricated alternatively?

3D printing is not necessary although it is the approach we employed. The text has been adjusted to clarify this point.

(7) Section 4.17.1. Can a schematic of the wells C05-E08 be provided?

In reflecting on this comment, we concluded that the description of the process for choosing how many wells to image was too prescriptive. We have made the language in this section more general so the reader can make their own choices for their experimental design in characterizing the induced strain. The choice of how many wells to image at a time, and how many times to image them, will depend on the reader's judgement and understanding of their application.

(8) Section 5.17. Better to say "0.033". Do the authors want to mix SI and Imperial units?

.33 has been replaced with 0.33. All imperial units have been converted to SI.

References

- 1 Sherman, S. A. *et al.* Stretch Injury of Human Induced Pluripotent Stem Cell Derived Neurons in a 96 Well Format. *Sci Rep.* **6** 34097, doi:10.1038/srep34097, (2016).
- 2 Morrison, G. *et al.* Evaluation of inter-batch differences in stem-cell derived neurons. *Stem Cell Res.* **16** (1), 140-148, doi:10.1016/j.scr.2015.12.025, (2016).
- 3 Wheeler, H. E., Wing, C., Delaney, S. M., Komatsu, M. & Dolan, M. E. Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells. *PLoS One.* **10** (2), e0118020, doi:10.1371/journal.pone.0118020, (2015).
- 4 Sirenko, O., Hesley, J., Rusyn, I. & Cromwell, E. F. High-content high-throughput assays for characterizing the viability and morphology of human iPSC-derived neuronal cultures. *Assay Drug Dev Technol.* **12** (9-10), 536-547, doi:10.1089/adt.2014.592, (2014).

From: Jack Phillips [<mailto:phillips.jack.k@gmail.com>]
Sent: 17 November 2017 23:22
To: Permissions@nature.com
Cc: jfinan@northshore.org
Subject: Reusing a published figure from a CCA article

Hello,

We've published a paper under the CCA open access license in Scientific Reports (doi: 10.1038/srep34097), and we want to know if we can re-use a figure from that in a future publication, and if so, what the conditions would be, or what additional attribution would be necessary. Thank you for your help,

-Jack Phillips

From: Journalpermissions <journalpermissions@springernature.com>
Date: Mon, Nov 20, 2017, 3:20 AM
Subject: RE: Reusing a published figure from a CCA article
To: Jack Phillips <phillips.jack.k@gmail.com>

Dear Jack,

Thank you for your email. This work is licensed under a Creative Commons Attribution 4.0 International License. **You may reuse this material without obtaining permission from Nature Publishing Group, providing that the author and the original source of publication are fully acknowledged, as per the terms of the license.** The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

Kind regards,
Oda

Oda Siqveland
Permissions Assistant

SpringerNature
The Campus, 4 Crinan Street, London N1 9XW,
United Kingdom
T +44 (0) 207 014 6851

<http://www.nature.com>
<http://www.springer.com>
<http://www.palgrave.com>

Creative Commons Corporation (“Creative Commons”) is not a law firm and does not provide legal services or legal advice. Distribution of Creative Commons public licenses does not create a lawyer-client or other relationship. Creative Commons makes its licenses and related information available on an “as-is” basis. Creative Commons gives no warranties regarding its licenses, any material licensed under their terms and conditions, or any related information. Creative Commons disclaims all liability for damages resulting from their use to the fullest extent possible.

Using Creative Commons Public Licenses

Creative Commons public licenses provide a standard set of terms and conditions that creators and other rights holders may use to share original works of authorship and other material subject to copyright and certain other rights specified in the public license below. The following considerations are for informational purposes only, are not exhaustive, and do not form part of our licenses.

Considerations for licensors: Our public licenses are intended for use by those authorized to give the public permission to use material in ways otherwise restricted by copyright and certain other rights. Our licenses are irrevocable. Licensors should read and understand the terms and conditions of the license they choose before applying it. Licensors should also secure all rights necessary before applying our licenses so that the public can reuse the material as expected. Licensors should clearly mark any material not subject to the license. This includes other CC-licensed material, or material used under an exception or limitation to copyright. [More considerations for licensors.](#)

Considerations for the public: By using one of our public licenses, a licensor grants the public permission to use the licensed material under specified terms and conditions. If the licensor’s permission is not necessary for any reason—for example, because of any applicable exception or limitation to copyright—then that use is not regulated by the license. Our licenses grant only permissions under copyright and certain other rights that a licensor has authority to grant. Use of the licensed material may still be restricted for other reasons, including because others have copyright or other rights in the material. A licensor may make special requests, such as asking that all changes be marked or described. Although not required by our licenses, you are encouraged to respect those requests where reasonable. [More considerations for the public.](#)

Creative Commons Attribution 4.0 International Public License

By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution 4.0 International Public License (“Public License”). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.

Section 1 – Definitions.

- a. **Adapted Material** means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.

- b. **Adapter's License** means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.
- c. **Copyright and Similar Rights** means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.
- d. **Effective Technological Measures** means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.
- e. **Exceptions and Limitations** means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.
- f. **Licensed Material** means the artistic or literary work, database, or other material to which the Licensors applied this Public License.
- g. **Licensed Rights** means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensors has authority to license.
- h. **Licensors** means the individual(s) or entity(ies) granting rights under this Public License.
- i. **Share** means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.
- j. **Sui Generis Database Rights** means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.
- k. **You** means the individual or entity exercising the Licensed Rights under this Public License. **Your** has a corresponding meaning.

Section 2 – Scope.

- a. **License grant.**
 - 1. Subject to the terms and conditions of this Public License, the Licensors hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:
 - A. reproduce and Share the Licensed Material, in whole or in part; and
 - B. produce, reproduce, and Share Adapted Material.
 - 2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.
 - 3. Term. The term of this Public License is specified in Section 6(a).
 - 4. Media and formats; technical modifications allowed. The Licensors authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensors waives and/or agrees not to assert any right or authority to forbid You from making technical

modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a)(4) never produces Adapted Material.

5. Downstream recipients.
 - A. Offer from the Licensor – Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.
 - B. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.
6. No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).
- b. **Other rights.**
 1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.
 2. Patent and trademark rights are not licensed under this Public License.
 3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties.

Section 3 – License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

- a. **Attribution.**
 1. If You Share the Licensed Material (including in modified form), You must:
 - A. retain the following if it is supplied by the Licensor with the Licensed Material:
 - i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);
 - ii. a copyright notice;
 - iii. a notice that refers to this Public License;
 - iv. a notice that refers to the disclaimer of warranties;
 - v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;
 - B. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and

- C. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.
2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.
3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.
4. If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.

Section 4 – Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

- a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database;
- b. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and
- c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.

For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 – Disclaimer of Warranties and Limitation of Liability.

- a. **Unless otherwise separately undertaken by the Licensor, to the extent possible, the Licensor offers the Licensed Material as-is and as-available, and makes no representations or warranties of any kind concerning the Licensed Material, whether express, implied, statutory, or other. This includes, without limitation, warranties of title, merchantability, fitness for a particular purpose, non-infringement, absence of latent or other defects, accuracy, or the presence or absence of errors, whether or not known or discoverable. Where disclaimers of warranties are not allowed in full or in part, this disclaimer may not apply to You.**
- b. **To the extent possible, in no event will the Licensor be liable to You on any legal theory (including, without limitation, negligence) or otherwise for any direct, special, indirect, incidental, consequential, punitive, exemplary, or other losses, costs, expenses, or damages arising out of this Public License or use of the Licensed Material, even if the Licensor has been advised of the possibility of such losses, costs, expenses, or damages. Where a limitation of liability is not allowed in full or in part, this limitation may not apply to You.**
- c. The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 – Term and Termination.

- a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.
- b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:
 1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or
 2. upon express reinstatement by the Licensor.

For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.

- c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.
- d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Section 7 – Other Terms and Conditions.


- a. The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.
- b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.

Section 8 – Interpretation.

- a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.
- b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.
- c. No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.
- d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.

Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect to apply one of its public licenses to material it publishes and in those instances will be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared under a Creative Commons public license or as otherwise permitted by the Creative Commons policies published at creativecommons.org/policies, Creative Commons does not authorize the use of the trademark “Creative Commons” or any other trademark or logo of Creative Commons without its prior written consent including, without limitation, in connection with any unauthorized modifications to any of its public licenses or any other arrangements, understandings, or agreements concerning use of licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.

Creative Commons may be contacted at creativecommons.org.



| | | | | | | | | | | | |
|----------------------------------------------------------------------------------------------------------------------------------------|------|-----------|------------------------------------------------|-------------------------------|--|-----------------------------------|--|-----------|-----------------------------|--|-------------|
| UNLESS OTHERWISE SPECIFIED: DIMENSIONS ARE IN INCHES SURFACE FINISH: TOLERANCES: LINEAR: ± 0.002 ANGULAR: ± 0.1 | | | FINISH: MACHINE FINISH TUMBLE DEBURR | | | DEBUR AND BREAK SHARP EDGES | | | DO NOT SCALE DRAWING | | REVISION 07 |
| | | | | | | | | | | | |
| | NAME | SIGNATURE | DATE | | | | | | TITLE: REMOVABLE PIN | | |
| DRAWN | SRO | | 01/07/15 | | | | | | | | |
| CHK'D | | | | | | | | | | | |
| APPV'D | | | | | | | | | | | |
| MFG | | | | | | | | | | | |
| Q.A | | | | MATERIAL: 6061-T6 ALUMINUM | | | | DWG NO. | SRO - 3021 | | A4 |
| | | | | WEIGHT: | | | | SCALE:4:1 | SHEET 1 OF 1 | | |

BOM-Injury Device, Plate press

| Category | Vendor | Catalog No. |
|-----------------|----------------------|-------------------|
| Computer | Advantech | SYS-2U2320-7A01 |
| Computer | Advantech | 96OT-MT-690120 |
| Computer | Advantech | 96KB-104U-KT-B-US |
| Computer | Advantech | 96MS-OP2-USB-LT2 |
| Controller | DigiKey | SW1963-ND |
| Controller | DigiKey | Z3749-ND |
| Controller | DigiKey | HM1362-ND |
| Controller | DigiKey | HM1360-ND |
| Controller | National Instruments | 781174--01 |
| Controller | National Instruments | 780917--01 |
| Controller | National Instruments | 780110-01 |
| Controller | National Instruments | 779351-01 |
| Controller | National Instruments | 779005-01 |
| Controller | National Instruments | 196917-01 |
| Controller | National Instruments | 779019-01 |
| Controller | National Instruments | 182219--05 |
| Controller | National Instruments | 784005-35 |
| Controller | National Instruments | 779953-35 |
| Controller | National Instruments | 781233-01 |
| Controller | National Instruments | 782803-01 |
| Enclosure | ServerRack.com | 3141-3-001-06 |
| Enclosure | ServerRack.com | 1922-3-400-01 |
| Enclosure | ServerRack.com | 3150-3-001-06 |
| Enclosure | ServerRack.com | HW1032-50-Cage |
| Motion Platform | BEI Kimco | LA43-67-000A |
| Motion Platform | Copley Controls | XSL-230-40 |
| Motion Platform | Hitek Hardware | KC3824 |
| Motion Platform | Hitek Hardware | KF3824 |
| Motion Platform | Hitek Hardware | KS3824 |
| Motion Platform | Hitek Hardware | BES3824-16 |
| Motion Platform | McMaster | 1374N35 |
| Motion Platform | McMaster | 1435A470 |
| Motion Platform | McMaster | 2030N14 |
| Motion Platform | McMaster | 3935K11 |
| Motion Platform | McMaster | 5779K652 |
| Motion Platform | McMaster | 5986K672 |
| Motion Platform | McMaster | 6294K433 |
| Motion Platform | McMaster | 85175K84 |
| Motion Platform | McMaster | 8685K47 |
| Motion Platform | McMaster | 8975K149 |
| Motion Platform | McMaster | 9002T120 |
| Motion Platform | McMaster | 90145A475 |
| Motion Platform | McMaster | 90145A540 |
| Motion Platform | McMaster | 91292A013 |
| Motion Platform | McMaster | 9151K510 |
| Motion Platform | McMaster | 92196A110 |
| Motion Platform | McMaster | 92196A113 |
| Motion Platform | McMaster | 92196A269 |
| Motion Platform | McMaster | 92196A272 |
| Motion Platform | McMaster | 92196A544 |

BOM-Injury Device, Plate press

| | | |
|-----------------|-------------------------------------------|--------------------|
| Motion Platform | McMaster | 92210A108 |
| Motion Platform | McMaster | 92210A622 |
| Motion Platform | McMaster | 93340A305 |
| Motion Platform | McMaster | 94035A167 |
| Motion Platform | McMaster | 94115A539 |
| Motion Platform | McMaster | 94115A547 |
| Motion Platform | McMaster | 9663K750 |
| Motion Platform | Misumi | A5052P-6F-INCHA-N |
| Motion Platform | Misumi | A5052P-4F2G-INCHA |
| Motion Platform | Misumi | A5052P-6F-INCHA-N |
| Motion Platform | Misumi | U-PBFU0.38-L2.25-T |
| Motion Platform | Misumi | A5052P-4F2G-INCHA |
| Motion Platform | Misumi | A5052P-4F2G-INCHA |
| Motion Platform | Misumi | A5052P-6F-INCHA-N |
| Motion Platform | Misumi | A5052P-4F2G-INCHA |
| Motion Platform | Misumi | A5052P-6F-INCHA-N |
| Motion Platform | Misumi | A5052P-6F-INCHA-N |
| Motion Platform | Renishaw | T1031-30A |
| Motion Platform | Renishaw | Ti0200A20A |
| Motion Platform | Renishaw | A-9653-0138 |
| Motion Platform | Renishaw | A-9653-0139 |
| Motion Platform | Renishaw | A-9531-0342 |
| Motion Platform | ThorLabs | CMS010 |
| Motion Platform | ThorLabs | CMS011 |
| Wiring | DigiKey | A2076-ND |
| Wiring | DigiKey | A31944-ND |
| Wiring | DigiKey | A31948-ND |
| Wiring | DigiKey | A31949-ND |
| Wiring | DigiKey | A31954-ND |
| Wiring | DigiKey | A31955-ND |
| Wiring | DigiKey | A1038-ND |
| Wiring | DigiKey | A1039-ND |
| Wiring | DigiKey | A1040-ND |
| Wiring | DigiKey | A1031-ND |
| Wiring | DigiKey | A1033-ND |
| Wiring | DigiKey | A1035-ND |
| Wiring | DigiKey | A31909CT-ND |
| Wiring | DigiKey | A31910CT-ND |
| Wiring | DigiKey | A31906CT-ND |
| Wiring | DigiKey | A31905CT-ND |
| Wiring | DigiKey | A34126-ND |
| Wiring | DigiKey | A34128-ND |
| Wiring | DigiKey | A34131-ND |
| Wiring | DigiKey | 3M1768-ND |
| Wiring | DigiKey | 3M1769-ND |
| Wiring | DigiKey | 3M10686-ND |
| Wiring | DigiKey | 3M10687-ND |
| Wiring | WAGO Products (On-Line Electronics, Inc.) | 721-204/026-000 |
| Wiring | WAGO Products (On-Line Electronics, Inc.) | 721-104/026-000 |
| Wiring | WAGO Products (On-Line Electronics, Inc.) | 721-605/000-042 |
| Wiring | WAGO Products (On-Line Electronics, Inc.) | 721-103/026-000 |

BOM-Injury Device, Plate press

| | | |
|-------------|-------------------------------------------|-----------|
| Wiring | WAGO Products (On-Line Electronics, Inc.) | 231-131 |
| Plate Press | McMaster | 8975K39 |
| Plate Press | McMaster | 8975K352 |
| Plate Press | McMaster | 8975K251 |
| Plate Press | McMaster | 8975K979 |
| Plate Press | McMaster | 8934K18 |
| Plate Press | McMaster | 96242A734 |
| Plate Press | McMaster | 92196A587 |
| Plate Press | McMaster | 90669A622 |
| Plate Press | McMaster | 91847A031 |
| Plate Press | McMaster | 92949A267 |
| Plate Press | McMaster | 90669A537 |
| Plate Press | McMaster | 90145A546 |
| Plate Press | McMaster | 97155A737 |
| Plate Press | McMaster | 2610T34 |
| Plate Press | McMaster | 9540K782 |
| Plate Press | McMaster | 5093A76 |
| Plate Press | McMaster | 92196A199 |
| Plate Press | McMaster | 92949A108 |
| Plate Press | McMaster | 8610K93 |
| Plate Press | McMaster | 3723T63 |
| Plate Press | W.B. Jones | 788 |

BOM-Injury Device, Plate press

| Description | Qty |
|----------------------------------------------------------------------------------------------------|-----|
| High Performance Intel® Core™ i7/i5/i3 2U Rackmount System with up to 3 PCI/PCle Expansion Slots | 1 |
| GENERAL DEVICES 20" RACK MOUNT SLIDE(G) | 1 |
| KEYTRONIC USB 104 KEY KEYBOARD BLACK(G) | 1 |
| INPUT DEVICE, LOGITECH M100 MOUSE OPTICAL USB(G) | 1 |
| AC/DC CONVERTER 5V 30W | 1 |
| PWR SUPPLY 60W 24V2.5AVAC100-240 | 1 |
| ALUMINUM DIN CLIP 2.95" | 4 |
| ALUMINUM DIN CLIP 3.94" | 4 |
| cRIO--9024, Real--Time PowerPC Controller for cRIO, 800 MHz | 1 |
| cRIO--9113, 4--slot Virtex--5 LX50 Reconfigurable Chassis for cRIO | 1 |
| NI 9514 - C Series Servo Drive Interface with Encoder Feedback | 1 |
| NI 9401 - 8 Ch, 5 V/TTL High-Speed Bidirectional Digital I/O Module | 1 |
| NI 9411 6-Ch ±5-24 V, 1 MHz, Diff./SE DI Module | 1 |
| NI 9977 C Series filler module | 2 |
| NI 9912: DIN Rail Kit for 4-Slot Chassis | 2 |
| E1 Ethernet Cable, Twisted--pair, 5 m | 1 |
| LabVIEW Embedded Control and Monitoring Suite, USB, Include 1 Year SSP | 1 |
| NI LabVIEW Statechart Module, Includes 1 Year SSP | 1 |
| EMI Suppression Ferrite, 7.0mm | 4 |
| EMI Suppression Ferrite for NI 9401 | 2 |
| Kendall Howard 3141-3-001-06 - 6U LINIER Fixed Wall Mount Cabinet - Solid Door | 1 |
| Kendall Howard 1922-3-400-01 - 1U 20" Vented Rack Mountable Sliding Shelf | 1 |
| Kendall Howard 3150-3-001-06 - 6U LINIER Wall Mount Vertical Rail Kit - Cage Nut | 1 |
| Rackmount Solutions HW1032-50-Cage - 10-32 Hardware Kit, 50 count screws and cage nuts | 1 |
| Voice Coil | 1 |
| Servo Drive | 1 |
| Kinematic Vee Groove | 1 |
| Kinematic Flat | 2 |
| Kinematic Cone | 1 |
| Ball End Set Screw | 4 |
| Multipurpose Neoprene Rubber Sheet, Adhesive-Back, with Certificate, 12" x 24", 1/8" Thick | 1 |
| Round Grip Pull Handle with Threaded Holes, Anodized Aluminum, 10" Wide Center-to-Center | 2 |
| CLAMPING HANDLE WITH INTERNAL THREAD 10-32 SIZE | 2 |
| Single Scale Vacuum Gauge with ABS Plastic Case, 1-1/2" Dial, 1/8 NPT Male Bottom Connection, 30-0 | 1 |
| Push-to-Connect Tube Fitting for Air, 90 Degree Elbow, for 1/4" Tube OD x 1/8 NPT Male | 1 |
| Fixed Alignment Linear Sleeve Bearing 6061 Aluminum, for 3/8" Shaft Diameter, 0.0005" Shaft Cleara | 4 |
| Bushing | 4 |
| Oil-Resistant Fire-Retardant Blended Foam Sheet, Soft Buna-N, 1/4" Thick | 1 |
| 12.00" X 12.00" X 0.125" - Ultem | 1 |
| 6061 Aluminum, 3/4" Thick x 12" Wide, 2 Feet Long | 1 |
| Helical Spring | 4 |
| 18-8 Stainless Steel Dowel Pin 1/8" Diameter, 1" Long | 1 |
| 18-8 Stainless Steel Dowel Pin 1/4" Diameter, 3/4" Long | 1 |
| 18-8 Stainless Steel Socket Head Screw M2 x 0.4 mm Thread, 20 mm Long | 1 |
| High-Pressure Nickel-Plated Brass Pipe Fitting, Right-Angle Tee Adapter, 1/8 NPTF Female x Male | 1 |
| 18-8 Stainless Steel Socket Head Screw 4-40 Thread Size, 1/2" Long | 1 |
| 18-8 Stainless Steel Socket Head Screw 4-40 Thread Size, 3/4" Long | 1 |
| 18-8 Stainless Steel Socket Head Screw 10-32 Thread Size, 1/2" Long | 1 |
| 18-8 Stainless Steel Socket Head Screw 10-32 Thread Size, 3/4" Long | 1 |
| 18-8 Stainless Steel Socket Head Screw, 1/4"-20 Thread Size, 1-1/4" Long | 1 |

BOM-Injury Device, Plate press

| | |
|-----------------------------------------------------------------------------------------------|-----|
| 18-8 Stainless Steel Hex Drive Flat Head Screw 4-40 Thread Size, 3/8" Long | 1 |
| 18-8 Stainless Steel Hex Drive Flat Head Screw 3/8"-16 Thread Size, 3/4" Long | 1 |
| Threaded Insert for differential screw drive | 4 |
| 18-8 Stainless Steel Precision Shoulder Screw, 3/16" Diameter 7/8" Long Shoulder, 8-32 Thread | 4 |
| Alloy Steel Nylon-Tip Set Screws, Black-Oxide, 1/4"-20 Thread, 5/8" Long | 1 |
| Alloy Steel Nylon-Tip Set Screws, Black-Oxide, 1/4"-20 Thread, 1" Long | 1 |
| Corrosion-Resistant Compression Spring Stock, 20" Overall Length, 0.375" OD, 0.305" ID | 1 |
| 3.00" X 0.75" X 0.375" - Aluminum | 1 |
| 7.00" X 6.00" X 0.50" - Aluminum | 1 |
| 3.50" X 1.00" X 0.375" - Aluminum | 1 |
| 2.375" X 0.375" OD - #10-32 Tap on Both Ends - Coated Aluminum | 8 |
| 6.00 X 4.75" X 0.375" - Aluminum | 1 |
| 6.00" X 3.00" X 0.875" - Aluminum | 1 |
| 5.25" X 0.6875" X 0.375" - Aluminum | 2 |
| 4.75" X 4.50" X 0.50" - Aluminum | 1 |
| 9.75" X 6.00" X 0.50" - Aluminum | 1 |
| 8.00" X 7.00" X 0.50" - Aluminum | 2 |
| Renishaw Tonic - Readhead | 1 |
| Renishaw Tonic - Interface Unit | 1 |
| P Limit Magnet | 2 |
| Q Limit Magnet | 2 |
| RGG-2 Epoxy Packet | 2 |
| Cable Tie Bases for 6 mm (1/4") Wide Ties (Qty. 250) | 1 |
| Releasable Cable Ties, 6 mm (1/4") wide. (Qty. 100) | 1 |
| CONN D-SUB HOUSING PLUG 15POS | 4 |
| CONN D-SUB HOUSING PLUG 26POS | 4 |
| CONN D-SUB HOUSING RECEPT 15POS | 4 |
| CONN D-SUB HOUSING RECEPT 26POS | 4 |
| CONN D-SUB PIN 22-28AWG GOLD | 100 |
| CONN D-SUB SOCKET 22-28AWG GOLD | 100 |
| CONN D-SUB HOUSING PLUG 9POS | 4 |
| CONN D-SUB HOUSING PLUG 15POS | 4 |
| CONN D-SUB HOUSING PLUG 25POS | 4 |
| CONN D-SUB HOUSING RECEPT 9POS | 4 |
| CONN D-SUB HOUSING RECEPT 15POS | 4 |
| CONN D-SUB HOUSING RECEPT 25POS | 4 |
| CONTACT PIN 24-28AWG CRIMP GOLD | 100 |
| CONN PIN 20-24AWG GOLD CRIMP | 100 |
| CONN SOCKET 24-28AWG GOLD CRIMP | 100 |
| CONN SOCKET 20-24AWG GOLD CRIMP | 100 |
| CONN BACKSHELL DB9 DIE CAST | 4 |
| CONN BACKSHELL DB15 DIE CAST | 4 |
| CONN BACKSHELL DB25 DIE CAST | 4 |
| CONN MDR PLUG 20POS SLD CUP | 4 |
| CONN MDR PLUG 26POS SLD CUP | 4 |
| CONN BACKSHELL 20POS 180DEG SHLD | 4 |
| CONN BACKSHELL 26POS 180DEG SHLD | 4 |
| MOD F-CONN V0 POLARIZED | 2 |
| MOD F-CONN V0 POLARIZED | 2 |
| HDR W/C-C V0 w/GROUND | 2 |
| MOD F-CONN V0 POLARIZED | 2 |

BOM-Injury Device, Plate press

| | |
|-----------------------------------------------------------------------------------------------|---|
| PUSH BUTTON FOR F-CONN/M-CONN;LOOSE | 2 |
| Multipurpose 6061 Aluminum, Rectangular Bar, 1" x 2-1/2", 2' Long | 1 |
| Multipurpose 6061 Aluminum, Rectangular Bar, 1" x 5", 2' Long | 1 |
| Multipurpose 6061 Aluminum, Rectangular Bar, 1-1/4" x 4", 2' Long | 1 |
| Multipurpose 6061 Aluminum, Rectangular Bar, 1-1/4" x 6", 2' Long | 1 |
| Tight-Tolerance 304 Stainless Steel Rod, Precision Ground Finish, 3/4" Diameter, 2' Long | 1 |
| 12 Point Flange Head Cap Screw, Type 304 Stainless Steel, 3/8"-16 Thread, 1/2" Long, Fully | 1 |
| 18-8 Stainless Steel Socket Head Cap Screw, 5/16"-18 Thread, 1-1/2" Length, packs of 10 | 1 |
| 18-8 Stainless Steel Brass-Tip Set Screws 3/8"-16 Thread, 3/4" Long | 1 |
| 18-8 Stainless Steel Thin Hex Nut, 3/8"-16 Thread Size, 9/16" Width, 7/32" Height, packs of 1 | 1 |
| 18-8 Stainless Steel Button-Head Socket Cap Screw, 10-32 Thread, 5/8" Length, packs of 10 | 1 |
| Conformable Soft Brass-Tip Set Screw, 18-8 Stainless Steel, 1/4"-20 Thread, 1/2" Long, pack | 1 |
| 18-8 Stainless Steel Dowel Pin, 1/4" Diameter, 1-1/2" Length, packs of 10 | 1 |
| Plastic Dowel Pin, 5/16" Diameter, 3/4" Length, Acetal, packs of 50 | 1 |
| Acetal Sleeve Bearing for 3/4" Shaft Diameter, 1" OD, 3/4" Length | 4 |
| Rubber Bumper with Unthreaded Hole, Heavy Duty, SBR, Steel Washer, 13/16" OD, 13/16" H | 1 |
| Push/Pull Action Toggle Clamp, Hole Mounted, 700 lb Maximum Hold Capacity, 5-5/8" Height | 1 |
| 18-8 Stainless Steel Socket Head Screw 8-32 Thread Size, 1" Long | 1 |
| 18-8 Stainless Steel Button Head Hex Drive Screw 4-40 Thread Size, 3/8" Long | 1 |
| Weather-Resistant EPDM Rubber Sheet with Adhesive-Back, 12" x 12", 1/8" Thick | 1 |
| 17-4 PH Stainless Steel Shim Stock 4" x 60" Roll, 0.031" Thick | 1 |
| Compression Spring - P/N 788, 0.968OD, 0.080 302/304 stainless steel, 20.000 overall length | 1 |

National Instruments - cRIO 9514 - Control Signals - MDR 20

National Instruments Corp.
 11500 N Mopac Expressway
 Austin, TX 78759-3504
 1-888-280-7645
 1-512-683-8411
<http://www.ni.com/>

MDR - 20

From: National Instruments NI - cRIO Servo Interface - 9514 - Operating Instructions - 374988e.pdf

Page: 10

| | | | | | | |
|----|------------------|---|-------------------------|----|-----------------------|-----------|
| 1 | Forward Limit | • | RENISHAW - DSUB | 10 | Limits, Q | HDR 11-12 |
| 2 | Home | - | - | - | - | |
| 3 | COM | • | System Power | 2 | 24Vdc GND | HDR 03-04 |
| 4 | Digital Input 0 | - | - | - | - | |
| 5 | COM | • | System Power | 2 | 24Vdc GND | HDR 03-04 |
| 6 | Encoder Index+ | • | Copley Xenus - J7 (XSL) | 20 | Multi-Mode Encoder X | HDR 23-24 |
| 7 | Encoder Index- | • | Copley Xenus - J7 (XSL) | 21 | Multi-Mode Encoder /X | HDR 25-26 |
| 8 | COM | • | System Power | 2 | 24Vdc GND | HDR 03-04 |
| 9 | +5V OUT | - | - | - | - | |
| 10 | Position Compare | - | - | - | - | |
| 11 | Reverse Limit | • | RENISHAW - DSUB | 11 | Limits, P | HDR 13-14 |
| 12 | Reserved | - | - | - | - | |
| 13 | Vsup | • | System Power | 1 | +24Vdc | HDR 01-02 |
| 14 | Reserved | - | - | - | - | |
| 15 | COM | - | System Power | 2 | 24Vdc GND | HDR 03-04 |
| 16 | Encoder Phase A+ | • | Copley Xenus - J7 (XSL) | 16 | Multi-Mode Encoder A | HDR 15-16 |
| 17 | Encoder Phase A- | • | Copley Xenus - J7 (XSL) | 17 | Multi-Mode Encoder /A | HDR 17-18 |
| 18 | Encoder Phase B+ | • | Copley Xenus - J7 (XSL) | 18 | Multi-Mode Encoder B | HDR 19-20 |
| 19 | Position Capture | - | - | - | - | |
| 20 | Encoder Phase B- | • | Copley Xenus - J7 (XSL) | 19 | Multi-Mode Encoder /B | HDR 21-22 |

HDR 07-08

HDR 07-08 DISCONNECT

HDR 07-08 DISCONNECT

HDR 07-08 DISCONNECT

National Instruments - cRIO 9514 - Control Signals - HD DSUB 15

National Instruments Corp.
 11500 N Mopac Expressway
 Austin, TX 78759-3504
 1-888-280-7645
 1-512-683-8411
<http://www.ni.com/>

HD DSUB - 15

From: National Instruments NI - cRIO Servo Interface - 9514 - Operating Instructions - 374988e.pdf

Page: 9

| | | | | | | | |
|----|-------------------|---|-------------------------|----|--------------|-----------|-----------|
| 1 | Drive Command COM | • | Copley Xenus - J7 (XSL) | 25 | Ref(-) Input | HDR 33-34 | |
| 2 | Drive Enable | • | ESTOP - DSUB 9 | 1 | DPDT | HDR 37-38 | |
| 3 | Reserved | - | - | - | - | | |
| 4 | Reserved | - | - | - | - | | |
| 5 | Reserved | - | - | - | - | | |
| 6 | Drive Command | • | Copley Xenus - J7 (XSL) | 24 | Ref(+) Input | HDR 31-32 | |
| 7 | COM | • | System Power | 2 | 24Vdc GND | HDR 03-04 | HDR 07-08 |
| 8 | Digital Input 1 | - | - | - | - | | |
| 9 | Reserved | - | - | - | - | | |
| 10 | Reserved | - | - | - | - | | |
| 11 | Reserved | - | - | - | - | | |
| 12 | Vsup | • | System Power | 1 | +24Vdc | HDR 01-02 | |
| 13 | Reserved | - | - | - | - | | |
| 14 | COM | • | System Power | 2 | 24Vdc GND | HDR 03-04 | HDR 07-08 |
| 15 | NC | - | - | - | - | | |

DISCONNECT

NA

Copley Controls
20 Dan Road
Canton, MA 02021, U.S.A.

Tel: 781 828 8090

Fax: 781 828 6547

<http://www.copleycontrols.com/>

DSUB 9

From: NA

Page: NA

| | | | | | |
|----|-------|---------------------------|---|--------------|-----------|
| 1 | | • NI 9514 - HD DSUB 15 | 2 | Drive Enable | HDR 37-38 |
| 2 | | • Copley Xenus - J7 (XSL) | 3 | Enable [IN1] | HDR 39-40 |
| 3 | +5VDC | | | | HDR 05-06 |
| 4 | GND | | | | HDR 07-08 |
| 5 | | | | | |
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |

Renishaw Tonic - Feedback Connector

Renishaw Inc.
5277 Trillium Blvd
Hoffman Estates, IL 60192
1-847-286-9953

www.renishaw.com

DB15 - Female

From Dc Renishaw Tonic - Linear Encoder - Tonic Installation - tonic_t1000_m-9653-9225-01-a(en).pdf

Page

13

| | | | | | |
|----|----------------------|---|-------------------------|----|-------------------------|
| 1 | Set-up | - | - | - | |
| 2 | Power, 0V (Pin 2,9) | • | System Power | 4 | 5Vdc GND HDR 07-08 |
| 3 | Alarm, E- | - | - | - | |
| 4 | Reference Mark, Z- | • | Copley Xenus - J8 (XSL) | 9 | Encoder /X Input |
| 5 | Incremental, B- | • | Copley Xenus - J8 (XSL) | 7 | Encoder /B Input |
| 6 | Incremental, A- | • | Copley Xenus - J8 (XSL) | 5 | Encoder /A Input |
| 7 | Power, +5V (Pin 7,8) | • | System Power | 3 | +5Vdc HDR 05-06 |
| 8 | Power, +5V (Pin 7,8) | • | System Power | 3 | +5Vdc HDR 05-06 |
| 9 | Power, 0V (Pin 2,9) | • | System Power | 4 | 5Vdc GND HDR 07-08 |
| 10 | Limits, Q | • | NI 9514 - MDR 20 | 1 | Forward Limit HDR 11-12 |
| 11 | Limits, P | • | NI 9514 - MDR 20 | 11 | Reverse Limit HDR 13-14 |
| 12 | Reference Mark, Z+ | • | Copley Xenus - J8 (XSL) | 8 | Encoder X Input |
| 13 | Incremental, B+ | • | Copley Xenus - J8 (XSL) | 6 | Encoder B Input |
| 14 | Incremental, A+ | • | Copley Xenus - J8 (XSL) | 4 | Encoder A Input |
| 15 | NC | - | - | - | |

Copley Controls - Xenus XSL - Control Signals - J7

Copley Controls
 20 Dan Road
 Canton, MA 02021, U.S.A.
 Tel: 781 828 8090
 Fax: 781 828 6547
<http://www.copleycontrols.com/>

MDR - 26

From: Copley Controls - Servo Drive - Xenus XSL - Xenus Datasheet - Xenus-datasheet.pdf

Page: 13

| | | | | | | |
|----|-----------------------|------------------------|----|-------------------|-----------|------------|
| 1 | Frame Ground | • CHASSIS | | | | |
| 2 | Signal Ground | • System Power | 2 | 24Vdc GND | HDR 03-04 | |
| 3 | Enable [IN1] | • ESTOP - DSUB 9 | 2 | DPDT | HDR 39-40 | |
| 4 | GP Input [IN2] | - | - | - | | |
| 5 | GP Input [IN3] | - | - | - | | |
| 6 | GP Input [IN4] | - | - | - | | |
| 7 | HS Input [IN6] | - | - | - | | |
| 8 | HS Input [IN7] | - | - | - | | |
| 9 | HS Input [IN8] | - | - | - | | |
| 10 | HS Input [IN9] | - | - | - | | |
| 11 | HS Input [IN10] | - | - | - | | |
| 12 | GP Input [IN11] | - | - | - | | |
| 13 | [OUT1] | - | - | - | | |
| 14 | [OUT2] | - | - | - | | |
| 15 | [OUT3] | - | - | - | | |
| 16 | Multi-Mode Encoder A | • NI 9514 - MDR 20 | 16 | Encoder Phase A+ | HDR 15-16 | |
| 17 | Multi-Mode Encoder /A | • NI 9514 - MDR 20 | 17 | Encoder Phase A- | HDR 17-18 | |
| 18 | Multi-Mode Encoder B | • NI 9514 - MDR 20 | 18 | Encoder Phase B+ | HDR 19-20 | |
| 19 | Multi-Mode Encoder /B | • NI 9514 - MDR 20 | 20 | Encoder Phase B- | HDR 21-22 | |
| 20 | Multi-Mode Encoder X | • NI 9514 - MDR 20 | 6 | Encoder Index+ | HDR 23-24 | |
| 21 | Multi-Mode Encoder /X | • NI 9514 - MDR 20 | 7 | Encoder Index- | HDR 25-26 | |
| 22 | +5 Vdc @ 400mA | - | - | - | | |
| 23 | Signal Ground | • System Power | 2 | 24Vdc GND | HDR 03-04 | DISCONNECT |
| 24 | Ref(+) Input | • NI 9514 - HD DSUB 15 | 6 | Drive Command | HDR 31-32 | |
| 25 | Ref(-) Input | • NI 9514 - HD DSUB 15 | 1 | Drive Command COM | HDR 33-34 | |
| 26 | [IN12] GP Input | - | - | - | | |

Copley Controls - Xenus XSL - Motor Feedback - J8

Copley Controls
 20 Dan Road
 Canton, MA 02021, U.S.A.
 Tel: 781 828 8090
 Fax: 781 828 6547
<http://www.copleycontrols.com/>

MDR - 20

From: Copley Controls - Servo Drive - Xenus XSL - Xenus Datasheet - Xenus-datasheet.pdf

Page: 13

| | | | | | | | |
|----|-----------------------|-------------------|----|--------------------|-----------|------------|--|
| 1 | Frame Ground | • CHASSIS | | | | | |
| 2 | Signal Ground | • System Power | 2 | 24Vdc GND | HDR 03-04 | | |
| 3 | +5Vdc @ 400 mA | - | - | - | | | |
| 4 | Encoder A Input | • RENISHAW - DSUB | 14 | Incremental, A+ | | | |
| 5 | Encoder /A Input | • RENISHAW - DSUB | 6 | Incremental, A- | | | |
| 6 | Encoder B Input | • RENISHAW - DSUB | 13 | Incremental, B+ | | | |
| 7 | Encoder /B Input | • RENISHAW - DSUB | 5 | Incremental, B- | | | |
| 8 | Encoder X Input | • RENISHAW - DSUB | 12 | Reference Mark, Z+ | | | |
| 9 | Encoder /X Input | • RENISHAW - DSUB | 4 | Reference Mark, Z- | | | |
| 10 | Signal Ground | • System Power | 2 | 24Vdc GND | HDR 03-04 | DISCONNECT | |
| 11 | Digital Hall U | - | - | - | | | |
| 12 | Digital Hall V | - | - | - | | | |
| 13 | Digital Hall W | - | - | - | | | |
| 14 | [IN5] Temp Sensor | - | - | - | | | |
| 15 | Signal Ground | • System Power | 2 | 24Vdc GND | HDR 03-04 | DISCONNECT | |
| 16 | Encoder Sin(+) Input | - | - | - | | | |
| 17 | Encoder Sin (-) Input | - | - | - | | | |
| 18 | Encoder Cos (+) Input | - | - | - | | | |
| 19 | Encoder Cos (-) Input | - | - | - | | | |
| 20 | Signal Ground | • System Power | 2 | 24Vdc GND | HDR 03-04 | DISCONNECT | |

System Power Connector

Phoenix

4 Terminal Screw Connector

From:

Page:

| | | | | | | | |
|---|-----------|---|----------------------|-------|------|------------------|-------------|
| 1 | +24Vdc IN | • | NI 9514 - HD DSUB 15 | 12 | Vsup | NI 9514 - MDR 20 | 13 |
| 2 | 24Vdc GND | • | NI 9514 - HD DSUB 15 | 7, 14 | COM | NI 9514 - MDR 20 | 3, 5, 8, 15 |
| 3 | +5Vdc In | • | | | | | |
| 4 | 5Vdc GND | • | | | | | |

| | | | | | | |
|------|-------------------------|-------|---------------|-------------------------|---------------|---------------|
| Vsup | | | | | | |
| COM | Copley Xenus - J7 (XSL) | 2, 23 | Signal Ground | Copley Xenus - J8 (XSL) | 2, 10, 15, 20 | Signal Ground |

Copley Controls - Xenus XSL - Control Signals - J7

Copley Controls

20 Dan Road

Canton, MA 02021, U.S.A.

Tel: 781 828 8090

Fax: 781 828 6547

<http://www.copleycontrols.com/>

HD DSUB - 26

From: Copley Controls - Servo Drive - Xenus XTL - DataSheet - Xenus_XTL.pdf

Page: 18

| | | |
|----|------------------|-----|
| 1 | Frame Gnd | • |
| 2 | Ref (-) | • |
| 3 | Ref (+) | • |
| 4 | [IN1] Enable | • |
| 5 | [IN2] GP | - - |
| 6 | [IN3] GP | - - |
| 7 | [IN4] GP | - - |
| 8 | [IN11] GP | - - |
| 9 | [IN12] GP | - - |
| 10 | [IN6] HS | - - |
| 11 | [IN7] HS | - - |
| 12 | [IN8] HS | - - |
| 13 | [IN9] HS | - - |
| 14 | [IN10] HS | - - |
| 15 | Signal Gnd | • |
| 16 | [OUT1] | - - |
| 17 | [OUT2] | - - |
| 18 | [OUT3] | - - |
| 19 | Signal Gnd | • |
| 20 | +5 Vdc (Note 1) | - |
| 21 | Multi Encoder /X | • |
| 22 | Multi Encoder X | • |
| 23 | Multi Encoder /B | • |
| 24 | Multi Encoder B | • |
| 25 | Multi Encoder /A | • |
| 26 | Multi Encoder A | • |

Note 1: Total current drawn from +5 Vdc outputs cannot exceed 400 mA

Copley Controls - Xenus XSL - Motor Feedback - J8

Copley Controls
20 Dan Road
Canton, MA 02021, U.S.A.
Tel: 781 828 8090
Fax: 781 828 6547
<http://www.copleycontrols.com/>

HD DSUB - 15

From: Copley Controls - Servo Drive - Xenus XTL - DataSheet - Xenus_XTL.pdf

Page: 18

| | | |
|----|-----------------|-----|
| 1 | Frame Gnd | • |
| 2 | +5 Vdc (Note 1) | - - |
| 3 | Hall U | - - |
| 4 | +5 Vdc (Note 1) | - - |
| 5 | Signal Gnd | • |
| 6 | Hall V | - - |
| 7 | Encoder /X | • |
| 8 | Encoder X | • |
| 9 | Hall W | - - |
| 10 | [IN5] Motemp | - - |
| 11 | Encoder /B | • |
| 12 | Encoder B | • |
| 13 | Encoder /A | • |
| 14 | Encoder A | • |
| 15 | Signal Gnd | • |

• Note 1: Total current drawn from +5 Vdc outputs cannot exceed 400 mA

| <u>Pins</u> | <u>Signal</u> | <u>Connected to</u> |
|--------------------|-----------------------------------|----------------------------|
| 1 | 2 System Power (+24 V d.c.) | |
| 3 | 4 System Power (ground) | |
| 5 | 6 +5VDC | |
| 7 | 8 System Power (ground) | |
| 9 | 10 Empty | |
| 11 | 12 Renishaw Encoder Forward Limit | |
| 13 | 14 Renishaw Encoder Reverse Limit | |
| 15 | 16 Renishaw Encoder Output A | |
| 17 | 18 Renishaw Encoder Output A- | |
| 19 | 20 Renishaw Encoder Output B | |
| 21 | 22 Renishaw Encoder Output B- | |
| 23 | 24 Renishaw Encoder Reference | |
| 25 | 26 Renishaw Encoder Reference - | |
| 27 | 28 Empty | |
| 29 | 30 Empty | |
| 31 | 32 Drive Command from NI 9514 (+) | |
| 33 | 34 Drive Command from NI 9514 (-) | |
| 35 | 36 Empty | |
| 37 | 38 NI 9514 Enable | |
| 39 | 40 Xenus Enable | |